Patent Litigations
1. Arazlo patents expiration
ARAZLO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11311482 | June, 2023 | Notice of Filing Date Accorded | Bausch Health Ireland Limited et al. | Padagis Israel Pharmaceuticals Ltd. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11311482 | BAUSCH | Topical compositions and methods for treating skin diseases |
May, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 18, 2022 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 18 December, 2019
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Dosage: LOTION;TOPICAL
ARAZLO family patents
2. Ozempic patents expiration
What is Ozempic?
Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.
What is the Ozempic controversy?
The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.
OZEMPIC IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10335462 | March, 2023 | PO preliminary response filed | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| US8129343 | March, 2023 | PO preliminary response filed | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| US8536122 | March, 2023 | PO preliminary response filed | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| US8114833 | March, 2022 | Terminated-Settled | Novo Nordisk A/S | Fresenius Kabi USA, LLC |
| US8114833 | July, 2020 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
| US8114833 | December, 2019 | Terminated-Settled | Novo Nordisk A/S et al. | Pfizer Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 10 months from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(1 year, 3 months from now) | |
| US10335462 | NOVO | Use of long-acting GLP-1 peptides |
Jun, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-185) | Mar 28, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| New Indication(I-822) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 05 December, 2017
Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to imp...
Dosage: SOLUTION;SUBCUTANEOUS
OZEMPIC family patents
3. Rybelsus patents
expiration
RYBELSUS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8129343 | March, 2023 | PO preliminary response filed | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| US8536122 | March, 2023 | PO preliminary response filed | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 10 months from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
| M(M-252) | Jan 16, 2023 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 20 September, 2019
Treatment: Method of treating type 2 diabetes mellitus
Dosage: TABLET;ORAL
RYBELSUS family patents
4. Wegovy patents expiration
WEGOVY IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8129343 | March, 2023 | PO preliminary response filed | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| US8536122 | March, 2023 | PO preliminary response filed | Novo Nordisk A/S | Mylan Pharmaceuticals Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8536122 | NOVO | Acylated GLP-1 compounds |
Mar, 2026
(1 year, 10 months from now) | |
| US8129343 | NOVO | Acylated GLP-1 compounds |
Dec, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 04, 2024 |
| New Dosing Schedule(D-190) | Jul 21, 2026 |
| New Indication(I-935) | Mar 08, 2027 |
| New Patient Population(NPP) | Dec 23, 2025 |
| New Chemical Entity Exclusivity(NCE) | Dec 05, 2022 |
Drugs and Companies using SEMAGLUTIDE ingredient
NCE-1 date: 05 December, 2021
Market Authorisation Date: 04 June, 2021
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
WEGOVY family patents
5. Mavenclad patents expiration
MAVENCLAD IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10849919 | February, 2023 | Terminated-Settled | Ares Trading SA | Hopewell Pharma Ventures, Inc. et al. |
| US7713947 | January, 2023 | PO preliminary response filed | Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
| US8377903 | January, 2023 | PO preliminary response filed | Merck Serono SA | Hopewell Pharma Ventures, Inc. et al. |
| US7713947 | October, 2022 | Institution Denied | Merck Serono SA | TWi Pharmaceuticals, Inc. |
| US8377903 | October, 2022 | Institution Denied | Merck Serono SA | TWi Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8377903 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
May, 2026
(2 years from now) | |
| US7713947 | EMD SERONO INC | Cladribine regimen for treating multiple sclerosis |
Oct, 2026
(2 years from now) | |
| US10849919 | EMD SERONO INC | Cladribine regimen for treating progressive forms of multiple sclerosis |
Nov, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 29, 2022 |
Drugs and Companies using CLADRIBINE ingredient
Market Authorisation Date: 29 March, 2019
Treatment: Treating rrms or spms with oral cladribine: (i) 2-4 months induction with 1.7 mg/kg - 3.5 mg/kg cladribine; (ii) cladribine-free period of about 8-10 months; (iii) 2-4 months maintenance with about 1....
Dosage: TABLET;ORAL
MAVENCLAD family patents
6. Onureg patents expiration
ONUREG IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8846628 | February, 2023 | Trial Instituted | CELGENE CORPORATION et al. | Apotex Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8846628 | BRISTOL | Oral formulations of cytidine analogs and methods of use thereof |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-320) | Sep 01, 2027 |
| New Product(NP) | Sep 01, 2023 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not a...
Dosage: TABLET;ORAL
ONUREG family patents
7. Calquence patents expiration
CALQUENCE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10272083 | February, 2023 | Institution Denied | Acerta Pharma B.V. et al. | Sandoz Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-175) | Oct 31, 2024 |
| Orphan Drug Exclusivity(ODE-274) | Nov 21, 2026 |
| New Indication(I-817) | Nov 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with previously untreated small lymphocytic leukemia by administering 100 mg of acalabrutinib twice daily in combination with obinutuzumab
Dosage: CAPSULE;ORAL
CALQUENCE family patents
8. Calquence patents expiration
CALQUENCE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10272083 | February, 2023 | Institution Denied | Acerta Pharma B.V. et al. | Sandoz Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10272083 | ASTRAZENECA | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
Jan, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: 31 October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab by administering 100 mg of acalabrutinib twice daily
Dosage: TABLET;ORAL
CALQUENCE family patents
9. Venclexta patents expiration
VENCLEXTA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US11110087 | October, 2022 | Trial Instituted | Genentech, Inc. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US10993942 | February, 2022 | Final Written Decision | Genentech, Inc. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10993942 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| US11110087 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective Bcl-2 inhibitor |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-185) | Jun 08, 2025 |
| Orphan Drug Exclusivity(ODE-211) | Nov 21, 2025 |
| Orphan Drug Exclusivity(ODE-239) | May 15, 2026 |
| New Chemical Entity Exclusivity(NCE) | Apr 11, 2021 |
| Orphan Drug Exclusivity(ODE) | Apr 11, 2023 |
| New Indication(I-789) | Nov 21, 2021 |
| New Indication(I-795) | May 15, 2022 |
| M(M-265) | Oct 16, 2023 |
| Orphan Drug Exclusivity(ODE-114) | Apr 11, 2023 |
| M(M-228) | Jun 08, 2021 |
| New Indication(I-782) | Jun 08, 2021 |
Drugs and Companies using VENETOCLAX ingredient
NCE-1 date: 11 April, 2020
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll) by orally administering venetoclax to an adult according to a dose ramp-up that includes a dose of 50 mg per day for...
Dosage: TABLET;ORAL
VENCLEXTA family patents
10. Trulance patents expiration
TRULANCE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7041786 | October, 2022 | Final Written Decision | Bausch Health Ireland Limited et al. | MSN Laboratories Private Ltd. et al. |
| US9610321 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9616097 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9919024 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US9925231 | June, 2022 | Institution Denied | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| US7041786 | March, 2022 | Final Written Decision | Bausch Health Ireland Limited et al. | Mylan Pharmaceuticals Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7041786 | SALIX | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
Jan, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9610321 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
| US9919024 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
| US9925231 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Sep, 2031
(7 years from now) | |
| US9616097 | SALIX | Formulations of guanylate cyclase C agonists and methods of use |
Aug, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 19, 2022 |
| New Indication(I-764) | Jan 24, 2021 |
Drugs and Companies using PLECANATIDE ingredient
NCE-1 date: 19 January, 2021
Market Authorisation Date: 19 January, 2017
Treatment: Irritable bowel syndrome with constipation; Chronic idiopathic constipation
Dosage: TABLET;ORAL
TRULANCE family patents
11. Xarelto patents expiration
XARELTO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10828310 | September, 2022 | Final Written Decision | Bayer Pharma AG et al. | Teva Pharmaceuticals USA, Inc |
| US10828310 | September, 2022 | Final Written Decision | Bayer Pharma AG et al. | InvaGen Pharmaceuticals, Inc. et al. |
| US10828310 | February, 2022 | Final Written Decision | Bayer Pharma AG et al. | Mylan Pharmaceuticals Inc. et al. |
| US9539218 | May, 2018 | Terminated-Denied | Bayer Intellectual Property GmbH | Mylan Pharmaceuticals Inc. |
| US7157456 | October, 2016 | Terminated-Dismissed | Bayer Intellectual Property GmbH | Mylan Pharmaceuticals Inc |
| US9539218 | January, 2014 | Decision | Frank Misselwitz et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7157456 | JANSSEN PHARMS | Substituted oxazolidinones and their use in the field of blood coagulation |
Aug, 2024
(3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9539218 | JANSSEN PHARMS | Prevention and treatment of thromboembolic disorders |
Feb, 2034
(9 years from now) | |
| US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-867) | Aug 23, 2024 |
| Pediatric Exclusivity(PED) | Feb 23, 2025 |
| New Indication(I-824) | Oct 11, 2021 |
| New Dosing Schedule(D-168) | Oct 27, 2020 |
| New Indication(I-810) | Oct 11, 2022 |
| M(M-284) | Mar 10, 2023 |
| New Indication(I-660) | Nov 02, 2015 |
| New Indication(I-661) | Nov 02, 2015 |
| New Indication(I-662) | Nov 02, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jul 01, 2016 |
| New Indication(I-643) | Nov 04, 2014 |
Drugs and Companies using RIVAROXABAN ingredient
NCE-1 date: 24 February, 2024
Market Authorisation Date: 11 October, 2018
Treatment: Treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after a...
Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL
XARELTO family patents
12. Idhifa patents expiration
IDHIFA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10610125 | August, 2022 | Terminated-Settled | Servier Pharmaceuticals LLC et al. | Rigel Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | BRISTOL MYERS SQUIBB | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-151) | Aug 01, 2024 |
| Orphan Drug Exclusivity(ODE) | Aug 01, 2024 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2022 |
Drugs and Companies using ENASIDENIB MESYLATE ingredient
NCE-1 date: 01 August, 2021
Market Authorisation Date: 01 August, 2017
Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation
Dosage: TABLET;ORAL
IDHIFA family patents
13. Tibsovo patents expiration
TIBSOVO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10610125 | August, 2022 | Terminated-Settled | Servier Pharmaceuticals LLC et al. | Rigel Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-203) | Jul 20, 2025 |
| Orphan Drug Exclusivity(ODE-242) | May 02, 2026 |
| New Indication(I-875) | Aug 25, 2024 |
| New Indication(I-924) | Oct 24, 2026 |
| Orphan Drug Exclusivity(ODE-368) | Aug 25, 2028 |
| Orphan Drug Exclusivity(ODE-447) | Oct 24, 2030 |
| New Indication(I-893) | May 25, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 20, 2023 |
| New Indication(I-816) | May 02, 2022 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: 20 July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method for treating newly diagnosed aml with ivosidenib and azacitidine wherein the aml has an idh1 mutation capable of converting alpha-ketoglutarate to 2-hydroxyglutarate (2hg)
Dosage: TABLET;ORAL
TIBSOVO family patents
14. Saxenda patents expiration
SAXENDA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8114833 | March, 2022 | Terminated-Settled | Novo Nordisk A/S | Fresenius Kabi USA, LLC |
| US8114833 | July, 2020 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
| US8114833 | December, 2019 | Terminated-Settled | Novo Nordisk A/S et al. | Pfizer Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8114833 | NOVO | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 04, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
| New Product(NP) | Jan 25, 2017 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 25 January, 2014
Market Authorisation Date: 23 December, 2014
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
SAXENDA family patents
15. Victoza patents expiration
VICTOZA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8114833 | March, 2022 | Terminated-Settled | Novo Nordisk A/S | Fresenius Kabi USA, LLC |
| US8114833 | July, 2020 | Terminated-Settled | Novo Nordisk A/S | Pfizer Inc. |
| US8114833 | December, 2019 | Terminated-Settled | Novo Nordisk A/S et al. | Pfizer Inc. et al. |
| US9265893 | January, 2014 | Decision | Torben Stroem Hansen et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8114833 | NOVO NORDISK INC | Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
Aug, 2025
(1 year, 3 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-176) | Apr 22, 2019 |
| New Patient Population(NPP) | Jun 17, 2022 |
| New Indication(I-750) | Aug 25, 2020 |
| Pediatric Exclusivity(PED) | Dec 17, 2022 |
| M(M-115) | Apr 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Jan 25, 2015 |
Drugs and Companies using LIRAGLUTIDE ingredient
NCE-1 date: 17 December, 2021
Market Authorisation Date: 25 January, 2010
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
VICTOZA family patents
16. Lupkynis patents expiration
LUPKYNIS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10286036 | February, 2022 | Terminated-Settled | Aurinia Pharmaceuticals Inc. | Sun Pharmaceutical Industries Ltd. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10286036 | AURINIA | Protocol for treatment of lupus nephritis |
Dec, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2026 |
Drugs and Companies using VOCLOSPORIN ingredient
NCE-1 date: 22 January, 2025
Market Authorisation Date: 22 January, 2021
Treatment: Treatment of patients with active lupus nephritis
Dosage: CAPSULE;ORAL
LUPKYNIS family patents
17. Vascepa patents expiration
VASCEPA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8642077 | November, 2021 | Terminated-Settled | Amarin Pharmaceuticals Ireland Limited | Hikma Pharmaceuticals USA Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8642077 | AMARIN PHARMS | Stable pharmaceutical composition and methods of using same |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 26, 2017 |
| New Indication(I-819) | Dec 13, 2022 |
| New Product(NP) | Jul 26, 2015 |
Drugs and Companies using ICOSAPENT ETHYL ingredient
NCE-1 date: 26 July, 2016
Market Authorisation Date: 26 July, 2012
Treatment: Use of vascepa to reduce triglycerides in a mixed dyslipidemia adult patient with elevated triglyceride (tg) levels (>= 150 mg/dl) and on statin therapy
Dosage: CAPSULE;ORAL
VASCEPA family patents
18. Lumify patents expiration
LUMIFY IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8293742 | November, 2021 | Final Written Decision - Appealed | Eye Therapies, LLC et al. | Slayback Pharma LLC et al. |
| US9259425 | November, 2021 | Terminated-Settled | Eye Therapies, LLC | Slayback Pharma LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8293742 | BAUSCH AND LOMB INC | Preferential vasoconstriction compositions and methods of use |
Jul, 2030
(6 years from now) | |
| US9259425 | BAUSCH AND LOMB INC | Compositions and methods for eye whitening |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2020 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIFY family patents
19. Pedmark patents expiration
PEDMARK IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10596190 | October, 2021 | Final Written Decision | Oregon Health & Science University et al. | Hope Medical Enterprises, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596190 | FENNEC PHARMS INC | Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 20, 2025 |
| Orphan Drug Exclusivity(ODE-384) | Sep 20, 2029 |
Drugs and Companies using SODIUM THIOSULFATE ingredient
Market Authorisation Date: 20 September, 2022
Treatment: A method of reducing ototoxicity in a human pediatric patient about 5 years of age or under with localized medulloblastoma comprising administering sodium thiosulfate about six hours after administrat...
Dosage: SOLUTION;INTRAVENOUS
PEDMARK family patents
20. Thiola Ec patents expiration
THIOLA EC IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US11458104 | October, 2021 | Decision | Mission Pharmacal Company | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458104 | MISSION PHARMACAL | Enteric coated tiopronin tablet |
Nov, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Jun 28, 2026 |
Drugs and Companies using TIOPRONIN ingredient
Market Authorisation Date: 28 June, 2019
Treatment: A method of treating cystinuria by orally administering tiopronin with food to prevent cystine stone formation in adults and pediatric patients with severe homozygous cystinuria
Dosage: TABLET, DELAYED RELEASE;ORAL
THIOLA EC family patents
21. Levulan patents expiration
LEVULAN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10357567 | October, 2021 | Terminated-Dismissed | DUSA Pharmaceuticals, Inc. et al. | Biofrontera Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10357567 | DUSA | Methods for photodynamic therapy |
Jan, 2038
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-766) | Mar 09, 2021 |
| M(M-82) | Mar 12, 2013 |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Market Authorisation Date: 03 December, 1999
Treatment: Treatment of actinic keratoses of upper extremities by photodynamic therapy
Dosage: SOLUTION;TOPICAL
LEVULAN family patents
22. Austedo patents expiration
AUSTEDO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8524733 | September, 2021 | Terminated-Denied | Auspex Pharmaceuticals, Inc. | Apotex Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA BRANDED PHARM | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: NA
Dosage: TABLET;ORAL
AUSTEDO family patents
23. Austedo Xr patents expiration
AUSTEDO XR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8524733 | September, 2021 | Terminated-Denied | Auspex Pharmaceuticals, Inc. | Apotex Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(6 years from now) | |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
AUSTEDO XR family patents
24. Chantix patents expiration
CHANTIX IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US6890927 | June, 2021 | Terminated-Settled | Pfizer Inc. | Apotex Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(1 year, 11 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-192) | Dec 16, 2019 |
| Pediatric Exclusivity(PED) | Aug 22, 2022 |
| M(M-183) | Aug 12, 2019 |
| M(M-144) | Oct 15, 2017 |
| M(M-143) | Oct 15, 2017 |
| M(M-237) | Feb 22, 2022 |
| M(M-105) | Jul 22, 2014 |
Drugs and Companies using VARENICLINE TARTRATE ingredient
Market Authorisation Date: 10 May, 2006
Treatment: Aid to smoking cessation
Dosage: TABLET;ORAL
CHANTIX family patents
25. Qelbree patents expiration
QELBREE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US11324753 | February, 2021 | Decision | Supernus Pharmaceuticals, Inc. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11324753 | SUPERNUS PHARMS | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
Sep, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 02, 2026 |
| New Patient Population(NPP) | Apr 29, 2025 |
Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient
NCE-1 date: 02 April, 2025
Market Authorisation Date: 02 April, 2021
Treatment: For the treatment of attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
QELBREE family patents
26. Tyvaso patents expiration
TYVASO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10716793 | January, 2021 | Final Written Decision - Appealed | United Therapeutics Corporation | Liquidia Technologies, Inc. |
| US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
| US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
| US9339507 | June, 2017 | Terminated-Settled | United Therapeutics Corp. | Watson Laboratories, Inc. |
| US9358240 | June, 2017 | Terminated-Settled | United Therapeutics Corp. | Watson Laboratories, Inc. |
| US8497393 | October, 2015 | FWD Entered | United Therapeutics Corporation | SteadyMed Ltd. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
| US9339507 | UNITED THERAP | Treprostinil administration by inhalation |
Mar, 2028
(3 years from now) | |
| US9358240 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-856) | Mar 31, 2024 |
| M(M-145) | May 20, 2017 |
| Orphan Drug Exclusivity(ODE) | Jul 30, 2016 |
| New Dosage Form(NDF) | Jul 30, 2012 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 30 July, 2009
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: SOLUTION;INHALATION
TYVASO family patents
27. Tyvaso Dpi patents expiration
TYVASO DPI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10716793 | January, 2021 | Final Written Decision - Appealed | United Therapeutics Corporation | Liquidia Technologies, Inc. |
| US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
| US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716793 | UNITED THERAP | Treprostinil administration by inhalation |
May, 2027
(3 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension by administering treprostinil or a salt thereof by inhalation using a device
Dosage: POWDER;INHALATION
TYVASO DPI family patents
28. Cerdelga patents expiration
CERDELGA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US11458119 | November, 2020 | Decision | Hanlan Liu et al. | |
| US10888547 | April, 2019 | Decision | Genzyme Corporation | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11458119 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Nov, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10888547 | GENZYME CORP | Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Aug 19, 2021 |
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2019 |
| Orphan Drug Exclusivity(ODE-73) | Aug 19, 2021 |
Drugs and Companies using ELIGLUSTAT TARTRATE ingredient
NCE-1 date: 19 August, 2018
Market Authorisation Date: 19 August, 2014
Treatment: Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 extensive or intermediate metabolizers with 84 mg twice per day of eliglustat (equivalent to 100 mg of eliglustat tartrate twic...
Dosage: CAPSULE;ORAL
CERDELGA family patents
29. Cabenuva Kit patents expiration
CABENUVA KIT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US11389447 | October, 2020 | Decision | JANSSEN SCIENCES IRELAND UC | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11389447 | VIIV HLTHCARE | Aqueous suspensions of TMC278 |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2026 |
| New Patient Population(NPP) | Mar 29, 2025 |
| New Dosing Schedule(D-184) | Jan 31, 2025 |
Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient
NCE-1 date: 21 January, 2025
Market Authorisation Date: 21 January, 2021
Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
CABENUVA KIT family patents
30. Lutathera patents expiration
LUTATHERA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10596276 | October, 2020 | Institution Denied | Advanced Accelerator Applications SA | Evergreen Theragnostics, Inc. |
| US10596278 | October, 2020 | Terminated-Denied | Advanced Accelerator Applications SA | Evergreen Theragnostics, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596278 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(14 years from now) | |
| US10596276 | AAA USA INC | Stable, concentrated radionuclide complex solutions |
Jul, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-166) | Jan 26, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jan 26, 2023 |
Drugs and Companies using LUTETIUM LU 177 DOTATATE ingredient
NCE-1 date: 26 January, 2022
Market Authorisation Date: 26 January, 2018
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
LUTATHERA family patents
31. Elcys patents expiration
ELCYS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10653719 | September, 2020 | Institution Denied | Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
| US10583155 | June, 2020 | Terminated-Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10478453 | May, 2020 | Institution Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478453 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10583155 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10653719 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 April, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION;INTRAVENOUS
ELCYS family patents
32. Nouress patents expiration
NOURESS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10653719 | September, 2020 | Institution Denied | Exela Pharma Sciences LLC | Eton Pharmaceuticals, Inc. |
| US10583155 | June, 2020 | Terminated-Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals Inc. |
| US10478453 | May, 2020 | Institution Denied | Exela Pharma Sciences, LLC | Eton Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
| US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(14 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 December, 2019
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION;INTRAVENOUS
NOURESS family patents
33. Entresto patents expiration
ENTRESTO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8101659 | August, 2020 | Terminated-Denied | Novartis Pharmaceuticals Corporation | Biocon Pharma Limited |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8101659 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-82) | Feb 16, 2024 |
| Pediatric Exclusivity(PED) | Apr 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
| New Patient Population(NPP) | Oct 01, 2022 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
ENTRESTO family patents
34. Naproxen Sodium patents expiration
NAPROXEN SODIUM IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US11090280 | July, 2020 | Decision | PATHEON SOFTGELS INC | |
| US9693978 | January, 2018 | Terminated-Denied | Patheon Softgels Inc. | Catalent Pharma Solutions, Inc. |
| US9693979 | January, 2018 | Terminated-Denied | Patheon Softgels Inc. | Catalent Pharma Solutions, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090280 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 9 months from now) | |
| US9693979 | BIONPHARMA | Liquid dosage forms of sodium naproxen |
Mar, 2026
(1 year, 9 months from now) | |
| US9693978 | BIONPHARMA | Solvent system for enhancing the solubility of pharmaceutical agents |
Mar, 2026
(1 year, 9 months from now) | |
Drugs and Companies using NAPROXEN SODIUM ingredient
Market Authorisation Date: 17 February, 2006
Treatment: Temporary reduction of fever
Dosage: CAPSULE;ORAL
NAPROXEN SODIUM family patents
35. Janumet patents expiration
JANUMET IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET;ORAL
JANUMET family patents
36. Janumet Xr patents expiration
JANUMET XR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Feb 12, 2023 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate
Dosage: TABLET, EXTENDED RELEASE;ORAL
JANUMET XR family patents
37. Januvia patents expiration
JANUVIA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 16 October, 2006
Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor
Dosage: TABLET;ORAL
JANUVIA family patents
38. Juvisync patents expiration
JUVISYNC IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Apr, 2026
(1 year, 11 months from now) | |
Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 18 September, 2012
Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate
Dosage: TABLET;ORAL
JUVISYNC family patents
39. Steglujan patents expiration
STEGLUJAN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Sun Pharmaceutical Industries Ltd. et al. |
| US7326708 | June, 2020 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Dr. Reddy's Laboratories, Inc. et al. |
| US7326708 | June, 2020 | Terminated-Settled | Merck Sharp & Dohme Corp. | Teva Pharmaceuticals USA, Inc. |
| US7326708 | October, 2019 | Final Written Decision | Merck Sharp & Dohme Corp. et al. | Mylan Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
STEGLUJAN family patents
40. Latuda patents expiration
LATUDA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9815827 | June, 2020 | FWD Entered | Sumitomo Dainippon Pharma Co., Ltd. | Slayback Pharma LLC |
| US9555027 | April, 2017 | Terminated-Settled | Sumitomo Dainippon Pharma Co., Ltd. | Par Pharmaceutical, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9815827 | SUNOVION PHARMS INC | Agent for treatment of schizophrenia |
Feb, 2024
(2 months ago) | |
| US9555027 | SUNOVION PHARMS INC | Pharmaceutical composition |
May, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-134) | Apr 26, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2015 |
| M(M-195) | Jan 27, 2020 |
| New Patient Population(NPP) | Mar 05, 2021 |
| New Indication(I-674) | Jun 28, 2016 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
Drugs and Companies using LURASIDONE HYDROCHLORIDE ingredient
NCE-1 date: 28 July, 2019
Market Authorisation Date: 07 December, 2011
Treatment: Treatment of schizophrenia
Dosage: TABLET;ORAL
LATUDA family patents
41. Zynrelef Kit patents expiration
ZYNRELEF KIT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US11083730 | May, 2020 | Decision | Heron Therapeutics, Inc. | |
| US11083797 | May, 2020 | Decision | Heron Therapeutics, Inc. | |
| US10898575 | December, 2019 | Decision | Heron Therapeutics, Inc. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10898575 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US11083797 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US11083730 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 12, 2024 |
| New Indication(I-933) | Jan 23, 2027 |
Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient
Market Authorisation Date: 12 May, 2021
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarti...
Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR
ZYNRELEF KIT family patents
42. Orenitram patents expiration
ORENITRAM IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
| US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
| US8497393 | October, 2015 | FWD Entered | United Therapeutics Corporation | SteadyMed Ltd. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
| New Dosage Form(NDF) | Dec 20, 2016 |
| New Indication(I-820) | Oct 18, 2022 |
| New Dosing Schedule(D-156) | Jan 28, 2019 |
| New Dosing Schedule(D-157) | Jan 28, 2019 |
| Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
ORENITRAM family patents
43. Remodulin patents expiration
REMODULIN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9593066 | March, 2020 | Terminated-Denied | United Therapeutics Corp. | Liquidia Technologies, Inc. |
| US9604901 | March, 2020 | FWD Entered | United Therapeutics Corp. | Liquidia Technolgies, Inc. |
| US8497393 | October, 2015 | FWD Entered | United Therapeutics Corporation | SteadyMed Ltd. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
| US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
| US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 28 September, 2023
Treatment: NA
Dosage: INJECTABLE;IV (INFUSION), SUBCUTANEOUS; SOLUTION;INTRAVENOUS, SUBCUTANEOUS
REMODULIN family patents
44. Invega Sustenna patents expiration
INVEGA SUSTENNA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9439906 | February, 2020 | Terminated-Denied | Janssen Pharmaceutica NV | Mylan Laboratories Ltd. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9439906 | JANSSEN PHARMS | Dosing regimen associated with long acting injectable paliperidone esters |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2011 |
| New Indication(I-698) | Nov 12, 2017 |
| M(M-215) | Dec 20, 2020 |
| New Dosage Form(NDF) | Jul 31, 2012 |
| Pediatric Exclusivity(PED) | Jan 31, 2013 |
| M(M-119) | Aug 29, 2015 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
NCE-1 date: 01 February, 2012
Market Authorisation Date: 31 July, 2009
Treatment: Treatment of schizophrenia
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA SUSTENNA family patents
45. Dymista patents expiration
DYMISTA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8163723 | January, 2020 | Terminated-Denied | Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US8168620 | January, 2020 | Terminated-Denied | Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US9259428 | January, 2020 | Terminated-Denied | Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US9901585 | January, 2020 | Terminated-Denied | Cipla Limited | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC |
| US8168620 | February, 2017 | Terminated-Settled | Cipla Limited | Argentum Pharmaceuticals LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9259428 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(10 months ago) | |
| US9901585 | MYLAN SPECIALITY LP | Combination of azelastine and fluticasone for nasal administration |
Jun, 2023
(10 months ago) | |
| US8163723 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Aug, 2023
(8 months ago) | |
| US8168620 | MYLAN SPECIALITY LP | Combination of azelastine and steroids |
Feb, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Feb 20, 2018 |
| Pediatric Exclusivity(PED) | Aug 20, 2018 |
| New Combination(NC) | May 01, 2015 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 01 May, 2012
Treatment: Treatment of seasonal allergic rhinitis
Dosage: SPRAY, METERED;NASAL
DYMISTA family patents
46. Pataday Once Daily Relief patents expiration
PATADAY ONCE DAILY RELIEF IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9533053 | December, 2019 | Terminated-Denied | Novartis AG | AYLA PHARMA LLC |
| US8791154 | June, 2018 | Terminated-Settled | Alcon Research Ltd. | Cipla Limited |
| US9533053 | June, 2018 | Terminated-Settled | Alcon Research Ltd. | Cipla Limited |
| US8791154 | August, 2016 | Terminated-Settled | Alcon Research, Ltd. | Apotex, Inc. |
| US8791154 | February, 2016 | Terminated-Settled | Alcon Research, Ltd. | Argentum Pharmaceuticals, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791154 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
| US9533053 | ALCON LABS INC | High concentration olopatadine ophthalmic composition |
May, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2018 |
| Pediatric Exclusivity(PED) | Jul 30, 2018 |
Drugs and Companies using OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 2015
Treatment: Treatment of ocular itching associated with allergic conjunctivitis
Dosage: SOLUTION/DROPS;OPHTHALMIC
PATADAY ONCE DAILY RELIEF family patents
47. Cubicin patents expiration
CUBICIN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9138456 | November, 2019 | Terminated-Denied | Cubist Pharmaceuticals LLC | Amneal Pharmaceuticals LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-211) | Sep 01, 2020 |
| New Patient Population(NPP) | Mar 29, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: NA
Dosage: POWDER;INTRAVENOUS
CUBICIN family patents
48. Cubicin Rf patents expiration
CUBICIN RF IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9138456 | November, 2019 | Terminated-Denied | Cubist Pharmaceuticals LLC | Amneal Pharmaceuticals LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138456 | CUBIST PHARMS LLC | Lipopeptide compositions and related methods |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-211) | Sep 01, 2020 |
| New Patient Population(NPP) | Mar 29, 2020 |
Drugs and Companies using DAPTOMYCIN ingredient
Market Authorisation Date: 12 September, 2003
Treatment: NA
Dosage: POWDER;INTRAVENOUS
CUBICIN RF family patents
49. Bosulif patents expiration
BOSULIF IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US11103497 | August, 2019 | Decision | Becker Hewes | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-444) | Sep 26, 2030 |
| New Product(NP) | Sep 26, 2026 |
| Pediatric Exclusivity(PED) | Mar 26, 2027 |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
Market Authorisation Date: 26 September, 2023
Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject...
Dosage: CAPSULE;ORAL; TABLET;ORAL
BOSULIF family patents
50. Aczone patents expiration
ACZONE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9517219 | June, 2019 | FWD Entered | Almirall, LLC | Mylan Pharmaceuticals Inc. |
| US9517219 | November, 2018 | FWD Entered | Almirall, LLC | Amneal Pharmaceuticals LLC |
| US9161926 | February, 2018 | FWD Entered | Almirall, LLC | Amneal Pharmceuticals LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9517219 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(9 years from now) | |
| US9161926 | ALMIRALL | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
Nov, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Feb 24, 2019 |
| New Patient Population(NPP) | Sep 10, 2022 |
Drugs and Companies using DAPSONE ingredient
Market Authorisation Date: 24 February, 2016
Treatment: Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
ACZONE family patents
51. Korlym patents expiration
KORLYM IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10195214 | May, 2019 | FWD Entered | Corcept Therapeutics, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8921348 | August, 2018 | FWD Entered | Corcept Therapeutics Inc. | Neptune Generics LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8921348 | CORCEPT THERAP | Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists |
Aug, 2028
(4 years from now) | |
| US10195214 | CORCEPT THERAP | Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors |
Jun, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-22) | Feb 17, 2019 |
| New Product(NP) | Feb 17, 2015 |
| Orphan Drug Exclusivity(ODE) | Feb 17, 2019 |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
KORLYM family patents
52. Epinephrine patents expiration
EPINEPHRINE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9283197 | April, 2019 | Terminated-Settled | Belcher Pharmaceuticals, LLC | Adamis Pharmaceuticals Corporation |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9283197 | BPI LABS | More potent and less toxic formulations of epinephrine and methods of medical use |
Aug, 2034
(10 years from now) | |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 04 February, 2022
Treatment: Induction and maintenance of mydriasis during intraocular surgery
Dosage: SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS
EPINEPHRINE family patents
53. Imbruvica patents expiration
IMBRUVICA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9795604 | March, 2019 | FWD Entered | Pharmacyclics LLC | Sandoz Inc. |
| US8754090 | April, 2015 | Terminated-Denied | Pharmacyclics, Inc. | Coalition for Affordable Drugs IV LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8754090 | PHARMACYCLICS LLC | Use of inhibitors of bruton's tyrosine kinase (Btk) |
Jun, 2031
(7 years from now) | |
| US9795604 | PHARMACYCLICS LLC | Methods of treating and preventing graft versus host disease |
Oct, 2034
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-405) | Aug 24, 2029 |
| ODE*(ODE*) | Aug 02, 2024 |
| New Patient Population(NPP) | Aug 24, 2025 |
| Pediatric Exclusivity(PED) | Feb 24, 2026 |
| M(M-236) | Jan 25, 2022 |
| New Dosing Schedule(D-176) | Aug 24, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 13, 2018 |
Drugs and Companies using IBRUTINIB ingredient
NCE-1 date: 24 February, 2025
Market Authorisation Date: 16 February, 2018
Treatment: Treatment of mantle cell lymphoma; Treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy
Dosage: TABLET;ORAL; CAPSULE;ORAL; SUSPENSION;ORAL
IMBRUVICA family patents
54. Tecfidera patents expiration
TECFIDERA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8399514 | March, 2019 | Terminated-Other | Biogen MA Inc. | Sawai USA, Inc. |
| US8399514 | July, 2018 | Final Written Decision on Remand | Biogen MA Inc. | Mylan Pharmaceuticals Inc. et al. |
| US8399514 | September, 2015 | FWD Entered | Biogen Idec MA Inc | Coalition For Affordable Drugs V LLC |
| US8399514 | May, 2015 | Terminated-Denied | Biogen MA Inc. | Coalition for Affordable Drugs V LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-260) | Feb 05, 2023 |
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2018 |
Drugs and Companies using DIMETHYL FUMARATE ingredient
NCE-1 date: 27 March, 2017
Market Authorisation Date: 27 March, 2013
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TECFIDERA family patents
55. Narcan patents expiration
NARCAN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9561177 | February, 2019 | Institution Denied | Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9629965 | February, 2019 | Final Written Decision | Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9775838 | February, 2019 | Institution Denied | Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9468747 | February, 2019 | Final Written Decision | Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9211253 | February, 2019 | Final Written Decision | Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9468747 | February, 2019 | Institution Denied | Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9629965 | February, 2019 | Institution Denied | Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| US9211253 | February, 2019 | Institution Denied | Opiant Pharmaceuticals, Inc. | Nalox-1 Pharmaceuticals, LLC et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629965 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9561177 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9468747 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9211253 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
| US9775838 | EMERGENT | Nasal drug products and methods of their use |
Mar, 2035
(10 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 24 January, 2017
Treatment: Use of naloxone hydrochloride for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Dosage: SPRAY, METERED;NASAL
NARCAN family patents
56. Lotemax Sm patents expiration
LOTEMAX SM IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10596107 | January, 2019 | Decision | Mohannad Shawer et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10596107 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Dec, 2036
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Feb 22, 2022 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 February, 2019
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
Dosage: GEL;OPHTHALMIC
LOTEMAX SM family patents
57. Onpattro patents expiration
ONPATTRO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8058069 | January, 2019 | Final Written Decision | Arbutus Biopharma Corporation | Moderna Therapeutics, Inc. |
| US9364435 | March, 2018 | FWD Entered | Arbutus Biopharma Corporation | Moderna Therapeutics, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9364435 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| US8058069 | ALNYLAM PHARMS INC | Lipid formulations for nucleic acid delivery |
Apr, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-197) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using PATISIRAN SODIUM ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis
Dosage: SOLUTION;INTRAVENOUS
ONPATTRO family patents
58. Xyzal Allergy 24hr patents expiration
XYZAL ALLERGY 24HR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8633194 | December, 2018 | FWD Entered | UCB Biopharma Sprl | Apotex Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8633194 | CHATTEM SANOFI | Pharmaceutical composition of piperazine derivatives |
Oct, 2027
(3 years from now) | |
Drugs and Companies using LEVOCETIRIZINE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 31 January, 2017
Treatment: NA
Dosage: SOLUTION;ORAL
XYZAL ALLERGY 24HR family patents
59. Briviact patents expiration
BRIVIACT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10729653 | November, 2018 | Decision | Serge Cuypers et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Aug 27, 2024 |
| New Chemical Entity Exclusivity(NCE) | May 12, 2021 |
Drugs and Companies using BRIVARACETAM ingredient
NCE-1 date: 12 May, 2020
Market Authorisation Date: 12 May, 2016
Treatment: NA
Dosage: TABLET;ORAL
BRIVIACT family patents
60. Kinevac patents expiration
KINEVAC IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US6803046 | November, 2018 | Terminated-Denied | Bracco Diagnostics Inc. | Maia Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6803046 | BRACCO | Sincalide formulations |
Aug, 2022
(1 year, 8 months ago) | |
KINEVAC family patents
61. Suboxone patents expiration
SUBOXONE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9687454 | November, 2018 | FWD Entered | Indivior UK Limited | Dr. Reddy’s Laboratories S.A. |
| US9687454 | November, 2018 | Terminated-Denied | Indivior UK Limited | Dr. Reddy's Laboratories S.A. |
| US8603514 | June, 2017 | Terminated-Denied | MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | June, 2017 | Terminated-Denied | MonoSol Rx, LLC | Par Pharmaceutical, Inc. |
| US8603514 | November, 2016 | Terminated-Adverse Judgment | MonoSol Rx, LLC | Mylan Technologies, Inc. |
| US8017150 | May, 2016 | Terminated-Denied | MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8475832 | May, 2016 | Terminated-Denied | Indivior UK Limited | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | May, 2016 | Terminated-Denied | MonoSol Rx, LLC | Dr. Reddy's Laboratories, Inc. |
| US8017150 | December, 2015 | Terminated-Denied | MONOSOL RX, LLC | Teva Parmaceuticals USA Inc. |
| US8603514 | December, 2015 | Terminated-Denied | MONOSOL RX LLC | Teva Pharmaceuticals USA Inc |
| US8475832 | December, 2015 | Terminated-Denied | Indivior UK Limited | Teva Pharmaceuticals USA, Inc. |
| US8475832 | June, 2014 | Terminated-Denied | RB Pharmaceuticals Limited | BioDelivery Sciences International, Inc. |
| US8475832 | January, 2014 | FWD Entered | RB Pharmaceuticals Limited | BioDelivery Sciences International, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8017150 | INDIVIOR | Polyethylene oxide-based films and drug delivery systems made therefrom |
Feb, 2023
(1 year, 2 months ago) | |
| US8603514 | INDIVIOR | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(30 days ago) | |
| US9687454 | INDIVIOR | Sublingual and buccal film compositions |
Aug, 2029
(5 years from now) | |
| US8475832 | INDIVIOR | Sublingual and buccal film compositions |
Mar, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 30, 2013 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 August, 2010
Treatment: Treatment of opioid dependence/sublingual or buccal application; This drug is administered by sublingual route to humans for maintenance treatment of opioid dependence
Dosage: FILM;BUCCAL, SUBLINGUAL
SUBOXONE family patents
62. Airduo Digihaler patents expiration
AIRDUO DIGIHALER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO DIGIHALER family patents
63. Airduo Respiclick patents expiration
AIRDUO RESPICLICK IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-61) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 12 July, 2019
Treatment: NA
Dosage: POWDER;INHALATION
AIRDUO RESPICLICK family patents
64. Armonair Digihaler patents expiration
ARMONAIR DIGIHALER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR DIGIHALER family patents
65. Armonair Respiclick patents expiration
ARMONAIR RESPICLICK IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 09, 2024 |
| New Strength(NS) | Jul 09, 2024 |
| Pediatric Exclusivity(PED) | Jan 09, 2025 |
| New Product(NP) | Jan 27, 2020 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 08 April, 2022
Treatment: NA
Dosage: POWDER;INHALATION
ARMONAIR RESPICLICK family patents
66. Proair Digihaler patents expiration
PROAIR DIGIHALER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR DIGIHALER family patents
67. Proair Hfa patents expiration
PROAIR HFA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 16, 2011 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 29 October, 2004
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
PROAIR HFA family patents
68. Proair Respiclick patents expiration
PROAIR RESPICLICK IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2018 |
| New Patient Population(NPP) | Apr 28, 2019 |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 21 December, 2018
Treatment: NA
Dosage: POWDER, METERED;INHALATION
PROAIR RESPICLICK family patents
69. Qvar 40 patents expiration
QVAR 40 IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 15 September, 2000
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
QVAR 40 family patents
70. Qvar 80 patents expiration
QVAR 80 IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | TEVA BRANDED PHARM | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 15 September, 2000
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
QVAR 80 family patents
71. Qvar Redihaler patents expiration
QVAR REDIHALER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561808 | October, 2018 | Decision | Declan Walsh et al. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561808 | NORTON WATERFORD | Dose counter for inhaler having an anti-reverse rotation actuator |
Jan, 2032
(7 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
QVAR REDIHALER family patents
72. Revlimid patents expiration
REVLIMID IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7968569 | September, 2018 | Terminated-Denied | Celgene Corporation | Alvogen Pine Brook LLC |
| US7189740 | August, 2018 | Terminated-Denied | Celgene Corporation | Dr. Reddy's Laboratories, Inc. |
| US8404717 | August, 2018 | Terminated-Denied | Celgene Corporation | Dr. Reddy's Laboratories, Inc |
| US9056120 | August, 2018 | Terminated-Denied | Celgene Corporation | Dr. Reddy's Laboratories, Inc. |
| US8741929 | February, 2018 | Terminated-Denied | Celgene Corporation | Apotex Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7189740 | BRISTOL MYERS SQUIBB | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
Apr, 2023
(1 year, 23 days ago) | |
| US9056120 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
Apr, 2023
(1 year, 23 days ago) | |
| US8404717 | BRISTOL MYERS SQUIBB | Methods of treating myelodysplastic syndromes using lenalidomide |
Apr, 2023
(1 year, 23 days ago) | |
| US7968569 | BRISTOL MYERS SQUIBB | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
Oct, 2023
(6 months ago) | |
| US8741929 | BRISTOL MYERS SQUIBB | Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-131) | Feb 22, 2024 |
| Orphan Drug Exclusivity(ODE-241) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-245) | May 28, 2026 |
| New Indication(I-706) | Feb 17, 2018 |
| New Indication(I-796) | May 28, 2022 |
| New Indication(I-797) | May 28, 2022 |
| Orphan Drug Exclusivity(ODE-49) | Jun 05, 2020 |
| Orphan Drug Exclusivity(ODE-88) | Feb 17, 2022 |
| New Indication(I-672) | Jun 05, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 05, 2020 |
| New Strength(NS) | Jun 05, 2016 |
Drugs and Companies using LENALIDOMIDE ingredient
Market Authorisation Date: 21 December, 2011
Treatment: Use of revlimid (lenalidomide) for the treatment of transfusion-dependent anemia in myelodysplastic syndromes (mds); Use of revlimid (lenalidomide) for treatment of patients with transfusion-dependent...
Dosage: CAPSULE;ORAL
REVLIMID family patents
73. Ravicti patents expiration
RAVICTI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9561197 | August, 2018 | Terminated-Settled | Horizon Therapeutics, LLC | Par Pharmaceutical, Inc. |
| US9561197 | January, 2018 | Terminated-Settled | Horizon Therapeutics, LLC | Lupin, Ltd. |
| US9095559 | July, 2017 | Terminated-Settled | Horizon Therapeutics, LLC | Par Pharmaceutical, Inc. |
| US9254278 | July, 2017 | Terminated-Settled | Horizon Therapeutics, LLC | Par Pharmaceutical, Inc. |
| US9326966 | July, 2017 | Terminated-Settled | Horizon Therapeutics, LLC | Par Pharmaceutical, Inc. |
| US9254278 | March, 2017 | Terminated-Settled | Horizon Therapeutics, LLC | Lupin Ltd. |
| US9326966 | March, 2017 | Terminated-Settled | Horizon Therapeutics, LLC | Lupin Ltd. |
| US9095559 | April, 2016 | FWD Entered | Horizon Therapeutics, Inc. | Lupin Ltd |
| US8404215 | December, 2015 | FWD Entered | ||
| US8642012 | December, 2015 | FWD Entered | ||
| US8404215 | April, 2015 | FWD Entered | Horizon Therapeutics, Inc. | Par Pharmaceutical, Inc. |
| US8642012 | April, 2015 | FWD Entered | Horizon Therapeutics, Inc. | Par Pharmaceutical, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561197 | HORIZON THERAP US | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Sep, 2030
(6 years from now) | |
| US8642012 | HORIZON THERAP US | Methods of treatment using ammonia-scavenging drugs |
Sep, 2030
(6 years from now) | |
| US9095559 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(7 years from now) | |
| US8404215 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging |
Mar, 2032
(7 years from now) | |
| US9326966 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(7 years from now) | |
| US9254278 | HORIZON THERAP US | Methods of therapeutic monitoring of nitrogen scavenging drugs |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-157) | Apr 28, 2024 |
| New Patient Population(NPP) | Dec 21, 2021 |
| Orphan Drug Exclusivity(ODE-42) | Feb 01, 2020 |
| NE(NE) | Feb 01, 2016 |
| Orphan Drug Exclusivity(ODE) | Feb 01, 2020 |
Drugs and Companies using GLYCEROL PHENYLBUTYRATE ingredient
Market Authorisation Date: 01 February, 2013
Treatment: Dosage adjustment of a nitrogen scavenging drug in the treatment of a urea cycle disorder; Treatment of a urea cycle disorder
Dosage: LIQUID;ORAL
RAVICTI family patents
74. Vimovo patents expiration
VIMOVO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9393208 | July, 2018 | Terminated-Other | Pozen Inc. | Dr. Reddy's Lab., Inc. |
| US9220698 | April, 2018 | FWD Entered | Horizon Pharma USA, Inc. | Dr. Reddy's Laboratories, Inc. |
| US9393208 | December, 2017 | FWD Entered | Horizon Pharma USA, Inc. | Mylan Pharmaceuticals Inc. |
| US9220698 | August, 2017 | Terminated-Other | Horizon Pharma USA, Inc. | Mylan Pharmaceuticals Inc. |
| US8852636 | August, 2015 | Terminated-Denied | Pozen Inc. | Lupin Pharmaceuticals Inc |
| US8858996 | August, 2015 | FWD Entered | Pozen Inc. | Lupin Pharmaceuticals Inc. |
| US8945621 | August, 2015 | FWD Entered | Pozen Inc | Coalition for Affordable Drugs VII LLC |
| US8852636 | August, 2015 | Terminated-Denied | Pozen Inc. | Coalition for Affordable Drugs VII LLC |
| US8858996 | June, 2015 | Terminated-Denied | Pozen Inc. | Coalition for Affordable Drugs VII LLC |
| US6926907 | May, 2015 | Terminated-Denied | POZEN Inc. | Coalition for Affordable Drugs VII LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8858996 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
May, 2022
(1 year, 11 months ago) | |
| US8852636 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May, 2022
(1 year, 11 months ago) | |
| US6926907 | HORIZON | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(1 year, 2 months ago) | |
| US9393208 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Sep, 2029
(5 years from now) | |
| US9220698 | HORIZON | Method for delivering a pharmaceutical composition to patient in need thereof |
Mar, 2031
(6 years from now) | |
| US8945621 | HORIZON | Method for treating a patient at risk for developing an NSAID-associated ulcer |
Oct, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 06, 2020 |
| New Combination(NC) | Apr 30, 2013 |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient
Market Authorisation Date: 30 April, 2010
Treatment: Relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer; Risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment; Risk-reduction o...
Dosage: TABLET, DELAYED RELEASE;ORAL
VIMOVO family patents
75. Minivelle patents expiration
MINIVELLE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9833419 | May, 2018 | Terminated-Settled | Noven Pharmaceuticals, Inc. | Mylan Technologies, Inc. |
| US9724310 | December, 2017 | Terminated-Settled | Noven Pharmaceuticals, Inc. | Mylan Technologies, Inc. |
| US9730900 | December, 2017 | Terminated-Settled | Noven Pharmaceuticals, Inc. | Mylan Technologies, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9724310 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9730900 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(4 years from now) | |
| US9833419 | NOVEN | Transdermal estrogen device and delivery |
Jul, 2028
(4 years from now) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 23 September, 2014
Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent ...
Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL
MINIVELLE family patents
76. Vivitrol patents expiration
VIVITROL IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7919499 | April, 2018 | Terminated-Settled | Alkermes Pharma Ireland Limited | Amneal Pharmaceuticals LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919499 | ALKERMES | Naltrexone long acting formulations and methods of use |
Oct, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-631) | Oct 12, 2013 |
Drugs and Companies using NALTREXONE ingredient
Market Authorisation Date: 13 April, 2006
Treatment: Treatment of alcohol dependence
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
VIVITROL family patents
77. Miebo patents expiration
MIEBO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10449164 | April, 2018 | Decision | Novaliq GmbH | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10449164 | BAUSCH AND LOMB INC | Methods of treating ocular disorders using semifluorinated alkanes |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
MIEBO family patents
78. Eliquis patents expiration
ELIQUIS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9326945 | April, 2018 | Terminated-Settled | Pfizer Inc. | Mylan Pharmaceuticals Inc. |
| US6967208 | August, 2015 | Terminated-Denied | Bristol-Myers Squibb Company | Coalition for Affordable Drugs IX, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6967208 | BRISTOL MYERS SQUIBB | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors |
Nov, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9326945 | BRISTOL MYERS SQUIBB | Apixaban formulations |
Feb, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-690) | Aug 21, 2017 |
| New Indication(I-661) | Aug 21, 2017 |
| New Indication(I-691) | Aug 21, 2017 |
| New Indication(I-681) | Mar 03, 2017 |
| New Chemical Entity Exclusivity(NCE) | Dec 28, 2017 |
Drugs and Companies using APIXABAN ingredient
NCE-1 date: 28 December, 2016
Market Authorisation Date: 28 December, 2012
Treatment: Prophylaxis of pulmonary embolism
Dosage: TABLET;ORAL
ELIQUIS family patents
79. Oxycontin patents expiration
OXYCONTIN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9492393 | February, 2018 | Terminated-Settled | Purdue Pharma L.P. | Kashiv Pharma, LLC |
| US9492392 | February, 2018 | Terminated-Settled | Purdue Pharma L.P. | Kashiv Pharma, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9492393 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492392 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-153) | Apr 16, 2016 |
| New Patient Population(NPP) | Aug 13, 2018 |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2010
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: TABLET, EXTENDED RELEASE;ORAL
OXYCONTIN family patents
80. Afinitor patents expiration
AFINITOR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8410131 | January, 2018 | Terminated-Settled | Novartis Pharmaceuticals Corporation | Hikma Pharmaceuticals PLC |
| US8410131 | June, 2017 | Terminated-Settled | Novartis Pharmaceuticals Corporation | Breckenridge Pharmaceutial, Inc. |
| US9006224 | March, 2017 | Terminated-Settled | Novartis AG | West-Ward Pharmaceuticals International Limited |
| US9006224 | March, 2017 | FWD Entered | Novartis AG | Argentum Pharmaceuticals LLC |
| US9006224 | July, 2016 | FWD Entered | Novartis AG | Par Pharmaceutical, Inc. |
| US9006224 | July, 2016 | Terminated-Denied | Novartis AG | Roxane Laboratories, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(1 year, 5 months from now) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-724) | Feb 26, 2019 |
| Orphan Drug Exclusivity(ODE-108) | Feb 26, 2023 |
| Orphan Drug Exclusivity(ODE-24) | Apr 26, 2019 |
| Orphan Drug Exclusivity(ODE-11) | May 05, 2018 |
| New Chemical Entity Exclusivity(NCE) | Mar 30, 2014 |
| New Indication(I-630) | Oct 29, 2013 |
| New Indication(I-655) | Jul 20, 2015 |
| New Indication(I-650) | Apr 26, 2015 |
| Orphan Drug Exclusivity(ODE) | Apr 26, 2019 |
| Pediatric Exclusivity(PED) | Oct 26, 2015 |
| New Indication(I-638) | May 05, 2014 |
Drugs and Companies using EVEROLIMUS ingredient
NCE-1 date: 26 October, 2014
Market Authorisation Date: 09 July, 2010
Treatment: Treatment of solid excretory system tumors; Advanced renal cell carcinoma (rcc), after failure of treatment with sunitinib or sorafenib; Treatment of patients with progressive neuroendocrine tumors of...
Dosage: TABLET;ORAL
AFINITOR family patents
81. Viibryd patents expiration
VIIBRYD IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8673921 | January, 2018 | Terminated-Denied | Merck Patentgesellschaft Mit Beschrankter Haftung | Argentum Pharmaceuticals LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8673921 | ABBVIE | Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride |
Jun, 2022
(1 year, 10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-146) | Mar 16, 2018 |
| M(M-254) | Jan 31, 2023 |
| Pediatric Exclusivity(PED) | Jul 31, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 21, 2016 |
Drugs and Companies using VILAZODONE HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 21 January, 2011
Treatment: NA
Dosage: TABLET;ORAL
VIIBRYD family patents
82. Hetlioz patents expiration
HETLIOZ IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10376487 | December, 2017 | Decision | Vanda Pharmaceuticals, Inc. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-330) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE) | Jan 31, 2021 |
| New Indication(I-850) | Dec 01, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2019 |
| Orphan Drug Exclusivity(ODE-59) | Jan 31, 2021 |
Drugs and Companies using TASIMELTEON ingredient
NCE-1 date: 31 January, 2018
Market Authorisation Date: 31 January, 2014
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food
Dosage: CAPSULE;ORAL
HETLIOZ family patents
83. Hetlioz Lq patents expiration
HETLIOZ LQ IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10376487 | December, 2017 | Decision | Vanda Pharmaceuticals, Inc. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10376487 | VANDA PHARMS INC | Method of treatment |
Jul, 2035
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-329) | Dec 01, 2027 |
| New Product(NP) | Dec 01, 2023 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food
Dosage: SUSPENSION;ORAL
HETLIOZ LQ family patents
84. Epclusa patents expiration
EPCLUSA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8889159 | December, 2017 | Terminated-Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. |
| US8735372 | November, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US9284342 | November, 2017 | Institution Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US8633309 | October, 2017 | Institution Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US8334270 | October, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US7964580 | October, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-376) | Jun 10, 2028 |
| M(M-277) | Apr 27, 2025 |
| Pediatric Exclusivity(PED) | Dec 10, 2028 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient
Market Authorisation Date: 10 June, 2021
Treatment: For the treatment of hepatitis c
Dosage: PELLETS;ORAL; TABLET;ORAL
EPCLUSA family patents
85. Harvoni patents expiration
HARVONI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8889159 | December, 2017 | Terminated-Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. |
| US9393256 | December, 2017 | Terminated-Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. |
| US8735372 | November, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US9284342 | November, 2017 | Institution Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US8633309 | October, 2017 | Institution Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US8334270 | October, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US7964580 | October, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
| US9393256 | GILEAD SCIENCES INC | Methods for treating HCV |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-263) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-262) | Aug 28, 2026 |
| Orphan Drug Exclusivity(ODE-264) | Aug 28, 2026 |
| New Dosing Schedule(D-177) | Nov 15, 2022 |
Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: PELLETS;ORAL; TABLET;ORAL
HARVONI family patents
86. Sovaldi patents expiration
SOVALDI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8889159 | December, 2017 | Terminated-Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. |
| US9284342 | November, 2017 | Institution Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US8633309 | October, 2017 | Institution Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US8334270 | October, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US7964580 | October, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-135) | Apr 07, 2024 |
| ODE*(ODE*) | Aug 28, 2026 |
| Pediatric Exclusivity(PED) | Oct 07, 2024 |
| New Patient Population(NPP) | Apr 07, 2020 |
| Orphan Drug Exclusivity(ODE) | Apr 07, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 06, 2018 |
Drugs and Companies using SOFOSBUVIR ingredient
NCE-1 date: 08 October, 2023
Market Authorisation Date: 28 August, 2019
Treatment: For the treatment of hepatitis c
Dosage: TABLET;ORAL; PELLETS;ORAL
SOVALDI family patents
87. Vosevi patents expiration
VOSEVI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8889159 | December, 2017 | Terminated-Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. |
| US8735372 | November, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US9284342 | November, 2017 | Institution Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US8633309 | October, 2017 | Institution Denied | Gilead Pharmasset LLC | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US8334270 | October, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| US7964580 | October, 2017 | Institution Denied | Gilead Pharmasset LLC et al. | Initiative for Medicines, Access & Knowledge (I-MAK), Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8334270 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US8735372 | GILEAD SCIENCES INC | NA |
Mar, 2028
(3 years from now) | |
| US7964580 | GILEAD SCIENCES INC | NA |
Mar, 2029
(4 years from now) | |
| US8889159 | GILEAD SCIENCES INC | Compositions and methods for treating hepatitis C virus |
Mar, 2029
(4 years from now) | |
| US8633309 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Mar, 2029
(4 years from now) | |
| US9284342 | GILEAD SCIENCES INC | Nucleoside phosphoramidates |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 18, 2022 |
Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient
NCE-1 date: 18 July, 2021
Market Authorisation Date: 18 July, 2017
Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; Treatment of a...
Dosage: TABLET;ORAL
VOSEVI family patents
88. Mydayis patents expiration
MYDAYIS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8846100 | December, 2017 | FWD Entered | Shire LLC | KVK-Tech, Inc. |
| US9173857 | December, 2017 | FWD Entered | Shire, LLC | KVK-Tech, Inc. |
| US8846100 | January, 2017 | Terminated-Settled | Shire, LLC | Amerigen Pharmaceuticals Limited |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173857 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
May, 2026
(2 years from now) | |
| US8846100 | TAKEDA PHARMS USA | Controlled dose drug delivery system |
Aug, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 20, 2020 |
| Pediatric Exclusivity(PED) | Mar 13, 2023 |
| M(M-248) | Sep 13, 2022 |
Market Authorisation Date: 20 June, 2017
Treatment: Treatment of attention deficit hyperactivity disorder
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
MYDAYIS family patents
89. Abraxane patents expiration
ABRAXANE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7820788 | November, 2017 | Terminated-Denied | Abraxis Biosciences, LLC | Cipla Ltd. |
| US7820788 | November, 2017 | Terminated-Settled | Abraxis BioScience, LLC | Apotex Inc. |
| US7923536 | November, 2017 | Terminated-Denied | Abraxis Biosciences, LLC | Cipla Ltd. |
| US7923536 | November, 2017 | Terminated-Settled | Abraxis Biosciences, LLC | Apotex Inc. |
| US8138229 | November, 2017 | Terminated-Denied | AbraxisBiosciences, LLC | Cipla Ltd. |
| US8138229 | November, 2017 | Terminated-Dismissed | Abraxis BioScience, LLC et al. | Apotex Inc. et al. |
| US7820788 | April, 2017 | Terminated-Settled | ABRAXIS BIOSCIENCE, LLC | Actavis LLC |
| US7923536 | April, 2017 | Terminated-Settled | ABRAXIS BIOSCIENCE, LLC | Actavis LLC |
| US8138229 | April, 2017 | Terminated-Settled | ABRAXIS BIOSCIENCE, LLC, | Actavis LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7923536 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
| US8138229 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Dec, 2023
(4 months ago) | |
| US7820788 | BRISTOL-MYERS | Compositions and methods of delivery of pharmacological agents |
Oct, 2024
(5 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 06, 2023 |
| M(M-14) | Dec 06, 2022 |
| New Indication(I-676) | Sep 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Sep 06, 2020 |
| Orphan Drug Exclusivity(ODE-52) | Sep 06, 2020 |
| New Indication(I-658) | Oct 11, 2015 |
Drugs and Companies using PACLITAXEL ingredient
Market Authorisation Date: 07 January, 2005
Treatment: Treatment of lung cancer; Treatment of breast cancer; Treatment of pancreatic cancer
Dosage: POWDER;INTRAVENOUS
ABRAXANE family patents
90. Myrbetriq patents expiration
MYRBETRIQ IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US6346532 | October, 2017 | Terminated-Denied | Astellas Pharma Inc. | Sawai Pharmaceutical Co., Ltd. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6346532 | APGDI | Amide derivatives or salts thereof |
Oct, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-855) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
| New Indication(I-777) | Apr 27, 2021 |
| New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
Drugs and Companies using MIRABEGRON ingredient
NCE-1 date: 26 September, 2023
Market Authorisation Date: 28 June, 2012
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
MYRBETRIQ family patents
91. Myrbetriq Granules patents expiration
MYRBETRIQ GRANULES IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US6346532 | October, 2017 | Terminated-Denied | Astellas Pharma Inc. | Sawai Pharmaceutical Co., Ltd. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6346532 | APGDI | Amide derivatives or salts thereof |
Mar, 2022
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 25, 2024 |
| Pediatric Exclusivity(PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
MYRBETRIQ GRANULES family patents
92. Gilenya patents expiration
GILENYA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9187405 | August, 2017 | Terminated-Other | ||
| US9187405 | August, 2017 | FWD Entered | Novartis Pharmaceuticals Corporation | Actavis Elizabeth LLC |
| US9187405 | June, 2017 | FWD Entered | Novartis AG | Argentum Pharmaceuticals LLC |
| US9187405 | February, 2017 | FWD Entered | Novartis AG | Apotex Inc. |
| US8324283 | December, 2014 | FWD Entered | Novartis AG | Apotex, Inc. |
| US8324283 | May, 2014 | FWD Entered | Novartis AG | TORRENT PHARMACEUTICALS LIMITED |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8324283 | NOVARTIS | Solid pharmaceutical compositions comprising a SIP receptor agonist and a sugar alcohol |
Mar, 2026
(1 year, 10 months from now) | |
| US9187405 | NOVARTIS | S1P receptor modulators for treating relasping-remitting multiple sclerosis |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 11, 2021 |
| New Patient Population(NPP) | May 11, 2021 |
| Pediatric Exclusivity(PED) | Nov 11, 2021 |
| M(M-106) | Jul 20, 2014 |
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2015 |
Drugs and Companies using FINGOLIMOD HYDROCHLORIDE ingredient
NCE-1 date: 11 November, 2020
Market Authorisation Date: 11 May, 2018
Treatment: Treatment of relapsing-remitting sclerosis (ms)
Dosage: CAPSULE;ORAL
GILENYA family patents
93. Qbrelis patents expiration
QBRELIS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9463183 | July, 2017 | FWD Entered | Silvergate Pharmaceuticals, Inc. | KVK-Tech, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9463183 | AZURITY | Lisinopril formulations |
Nov, 2035
(11 years from now) | |
Drugs and Companies using LISINOPRIL ingredient
Market Authorisation Date: 29 July, 2016
Treatment: NA
Dosage: SOLUTION;ORAL
QBRELIS family patents
94. Exservan patents expiration
EXSERVAN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8603514 | June, 2017 | Terminated-Denied | MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | June, 2017 | Terminated-Denied | MonoSol Rx, LLC | Par Pharmaceutical, Inc. |
| US8603514 | November, 2016 | Terminated-Adverse Judgment | MonoSol Rx, LLC | Mylan Technologies, Inc. |
| US8603514 | May, 2016 | Terminated-Denied | MonoSol Rx, LLC | Dr. Reddy's Laboratories, Inc. |
| US8603514 | December, 2015 | Terminated-Denied | MONOSOL RX LLC | Teva Pharmaceuticals USA Inc |
| US8765167 | October, 2014 | FWD Entered | MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 | Terminated-Denied | MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765167 | AQUESTIVE | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(2 months ago) | |
| US8603514 | AQUESTIVE | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(30 days ago) | |
Drugs and Companies using RILUZOLE ingredient
Market Authorisation Date: 22 November, 2019
Treatment: NA
Dosage: FILM;ORAL
EXSERVAN family patents
95. Kynmobi patents expiration
KYNMOBI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8603514 | June, 2017 | Terminated-Denied | MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | June, 2017 | Terminated-Denied | MonoSol Rx, LLC | Par Pharmaceutical, Inc. |
| US8603514 | November, 2016 | Terminated-Adverse Judgment | MonoSol Rx, LLC | Mylan Technologies, Inc. |
| US8603514 | May, 2016 | Terminated-Denied | MonoSol Rx, LLC | Dr. Reddy's Laboratories, Inc. |
| US8603514 | December, 2015 | Terminated-Denied | MONOSOL RX LLC | Teva Pharmaceuticals USA Inc |
| US8765167 | October, 2014 | FWD Entered | MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 | Terminated-Denied | MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765167 | SUMITOMO PHARMA AM | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(2 months ago) | |
| US8603514 | SUMITOMO PHARMA AM | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(30 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: NA
Dosage: FILM;SUBLINGUAL
KYNMOBI family patents
96. Sympazan patents expiration
SYMPAZAN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8603514 | June, 2017 | Terminated-Denied | MonoSol Rx, LLC | Dr. Reddy’s Laboratories, Inc. |
| US8603514 | June, 2017 | Terminated-Denied | MonoSol Rx, LLC | Par Pharmaceutical, Inc. |
| US8603514 | November, 2016 | Terminated-Adverse Judgment | MonoSol Rx, LLC | Mylan Technologies, Inc. |
| US8603514 | May, 2016 | Terminated-Denied | MonoSol Rx, LLC | Dr. Reddy's Laboratories, Inc. |
| US8603514 | December, 2015 | Terminated-Denied | MONOSOL RX LLC | Teva Pharmaceuticals USA Inc |
| US8765167 | October, 2014 | FWD Entered | MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| US8765167 | October, 2014 | Terminated-Denied | MonoSol Rx, LLC. | BioDelivery Sciences International, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765167 | OTTER PHARMS | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
Feb, 2024
(2 months ago) | |
| US8603514 | OTTER PHARMS | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
Apr, 2024
(30 days ago) | |
Drugs and Companies using CLOBAZAM ingredient
Market Authorisation Date: 01 November, 2018
Treatment: NA
Dosage: FILM;ORAL
SYMPAZAN family patents
97. Abilify Maintena Kit patents expiration
ABILIFY MAINTENA KIT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10525057 | June, 2017 | Decision | Raoufinia, Arash | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10525057 | OTSUKA PHARM CO LTD | Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-746) | Jul 27, 2020 |
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Treatment of schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY MAINTENA KIT family patents
98. Jublia patents expiration
JUBLIA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7214506 | May, 2017 | FWD Entered | Kaken Pharmaceutical Co., Ltd. | Argentum Pharmaceuticals LLC |
| US7214506 | November, 2016 | FWD Entered | Kaken Pharmaceutical Co., Ltd. | Acrux DDS Pty Ltd. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214506 | BAUSCH | Method for treating onychomycosis |
Feb, 2026
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 27, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jun 06, 2019 |
Drugs and Companies using EFINACONAZOLE ingredient
NCE-1 date: 06 June, 2018
Market Authorisation Date: 06 June, 2014
Treatment: Antimycotic uses, specifically treatment of onychomycosis
Dosage: SOLUTION;TOPICAL
JUBLIA family patents
99. Zioptan patents expiration
ZIOPTAN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US5886035 | May, 2017 | FWD Entered | Santen Pharmaceutical Co., Ltd. | Micro Labs Limited |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5886035 | THEA PHARMA | Difluoroprostaglandin derivatives and their use |
Dec, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 10, 2017 |
Drugs and Companies using TAFLUPROST ingredient
NCE-1 date: 11 February, 2016
Market Authorisation Date: 10 February, 2012
Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension
Dosage: SOLUTION/DROPS;OPHTHALMIC
ZIOPTAN family patents
100. Travatan Z patents expiration
TRAVATAN Z IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8268299 | March, 2017 | FWD Entered | Alcon Research, Ltd. | Argentum Pharmaceuticals LLC |
| US8268299 | July, 2013 | Terminated-Settled | ALCON RESEARCH, LTD. | Apotex Corp. |
| US8323630 | July, 2013 | Terminated-Settled | ALCON RESEARCH, LTD. | Apotex Corp. |
| US8388941 | July, 2013 | Terminated-Settled | Alcon Research, Ltd. | Apotex Corp. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8323630 | SANDOZ | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
| US8388941 | SANDOZ | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
| US8268299 | SANDOZ | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(5 years from now) | |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 21 September, 2006
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
TRAVATAN Z family patents
101. Precedex patents expiration
PRECEDEX IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8242158 | March, 2017 | Terminated-Denied | Hospira, Inc. | Fresenius Kabi USA, LLC |
| US8338470 | March, 2017 | Terminated-Denied | Hospira, Inc. | Fresenius Kabi USA, LLC |
| US8455527 | March, 2017 | Terminated-Denied | Hospira, Inc. | Fresenius Kabi USA, LLC |
| US8648106 | August, 2016 | Terminated-Denied | Hospira, Inc. | Amneal Pharmaceuticals LLC |
| US8242158 | August, 2016 | Terminated-Settled | Hospira, Inc. | Amneal Pharmaceuticals LLC |
| US8338470 | August, 2016 | Terminated-Settled | Hospira, Inc. | Amneal Pharmaceuticals LLC |
| US8455527 | August, 2016 | Terminated-Settled | Hospira, Inc. | Amneal Pharmaceuticals LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455527 | HOSPIRA | Methods of treatment using a dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US8242158 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US8338470 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| US8648106 | HOSPIRA | Dexmedetomidine premix formulation |
Jan, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 16, 2025 |
| New Indication(I-577) | Oct 17, 2011 |
| M(M-61) | Jun 17, 2016 |
| Pediatric Exclusivity(PED) | Dec 17, 2016 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 31 January, 2020
Treatment: Use for sedation
Dosage: INJECTABLE;INJECTION
PRECEDEX family patents
102. Levothyroxine Sodium patents expiration
LEVOTHYROXINE SODIUM IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9006289 | January, 2017 | Terminated-Settled | Fresenius Kabi USA, LLC | Mylan Institutional Inc. |
| US9168238 | January, 2017 | Terminated-Settled | Fresenius Kabi USA, LLC | Mylan Institutional Inc. |
| US9168239 | January, 2017 | Terminated-Settled | Fresenius Kabi USA LLC | Mylan Institutional Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9168238 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(8 years from now) | |
| US9168239 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(8 years from now) | |
| US9006289 | FRESENIUS KABI USA | Levothyroxine formulations |
Oct, 2032
(8 years from now) | |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 24 June, 2011
Treatment: NA
Dosage: POWDER;INTRAVENOUS
LEVOTHYROXINE SODIUM family patents
103. Symbicort patents expiration
SYMBICORT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7759328 | January, 2017 | Terminated-Denied | AstraZeneca AB | Complex Innovations, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7759328 | ASTRAZENECA | Composition for inhalation |
Jan, 2023
(1 year, 3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-582) | Feb 27, 2012 |
| M(M-210) | Sep 11, 2020 |
| New Patient Population(NPP) | Jan 27, 2020 |
| M(M-214) | Dec 20, 2020 |
| Pediatric Exclusivity(PED) | Jul 27, 2020 |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient
Market Authorisation Date: 21 July, 2006
Treatment: Use for the treatment of asthma and copd
Dosage: AEROSOL, METERED;INHALATION
SYMBICORT family patents
104. Restasis patents expiration
RESTASIS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9248191 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8642556 | January, 2017 | FWD Entered | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8642556 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US9248191 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Akorn, Inc. |
| US8629111 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Akorn, Inc. |
| US8629111 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8642556 | January, 2017 | FWD Entered | Allergan, Inc. | Akorn, Inc. |
| US8633162 | January, 2017 | FWD Entered | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US9248191 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8685930 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8633162 | January, 2017 | FWD Entered | Allergan, Inc. | Akorn, Inc. |
| US8629111 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8648048 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8685930 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8648048 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Akorn, Inc. |
| US8648048 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8633162 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8685930 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Akorn, Inc. |
| US8629111 | June, 2016 | Terminated-Settled | Allergan, Inc. | Argentum Pharmaceuticals LLC |
| US8685930 | June, 2016 | Terminated-Dismissed | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8642556 | June, 2016 | FWD Entered | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8633162 | June, 2016 | FWD Entered | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8648048 | June, 2016 | Terminated-Dismissed | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US9248191 | June, 2016 | Terminated-Dismissed | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8629111 | June, 2016 | Terminated-Dismissed | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8685930 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| US8633162 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| US8642556 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| US8648048 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| US8629111 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).; Increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
RESTASIS family patents
105. Restasis Multidose patents expiration
RESTASIS MULTIDOSE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9248191 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8642556 | January, 2017 | FWD Entered | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8642556 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US9248191 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Akorn, Inc. |
| US8629111 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Akorn, Inc. |
| US8629111 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8642556 | January, 2017 | FWD Entered | Allergan, Inc. | Akorn, Inc. |
| US8633162 | January, 2017 | FWD Entered | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US9248191 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8685930 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8633162 | January, 2017 | FWD Entered | Allergan, Inc. | Akorn, Inc. |
| US8629111 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8648048 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Teva Pharmaceuticals USA, Inc. |
| US8685930 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8648048 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Akorn, Inc. |
| US8648048 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8633162 | January, 2017 | Terminated-Settled | Allergan, Inc. | Famy Care Limited |
| US8685930 | January, 2017 | Terminated-Dismissed | Allergan, Inc. | Akorn, Inc. |
| US8629111 | June, 2016 | Terminated-Settled | Allergan, Inc. | Argentum Pharmaceuticals LLC |
| US8685930 | June, 2016 | Terminated-Dismissed | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8642556 | June, 2016 | FWD Entered | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8633162 | June, 2016 | FWD Entered | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8648048 | June, 2016 | Terminated-Dismissed | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US9248191 | June, 2016 | Terminated-Dismissed | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8629111 | June, 2016 | Terminated-Dismissed | Allergan, Inc. | Mylan Pharmaceuticals Inc. |
| US8685930 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| US8633162 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| US8642556 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| US8648048 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| US8629111 | June, 2015 | Terminated-Denied | Allergan, Inc. | Apotex Corp. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8648048 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US8633162 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US9248191 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US8629111 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US8685930 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
| US8642556 | ABBVIE | Methods of providing therapeutic effects using cyclosporin components |
Aug, 2024
(3 months from now) | |
Drugs and Companies using CYCLOSPORINE ingredient
Market Authorisation Date: 23 December, 2002
Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).
Dosage: EMULSION;OPHTHALMIC
RESTASIS MULTIDOSE family patents
106. Vabomere patents expiration
VABOMERE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10561675 | November, 2016 | Decision | Rempex Pharmaceuticals, Inc. | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10561675 | REMPEX | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 29, 2022 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 29, 2027 |
Drugs and Companies using MEROPENEM; VABORBACTAM ingredient
NCE-1 date: 29 August, 2026
Market Authorisation Date: 29 August, 2017
Treatment: Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae sp...
Dosage: POWDER;INTRAVENOUS
VABOMERE family patents
107. Abilify patents expiration
ABILIFY IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9125939 | November, 2016 | Terminated-Denied | Otsuka Pharmaceutical Co., Ltd. | Alkermes Pharma Ireland Limited |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
| New Indication(I-633) | Feb 16, 2014 |
| New Indication(I-616) | Nov 19, 2012 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: Acute treatment of manic and mixed episodes associated with bipolar i disorder
Dosage: TABLET;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY family patents
108. Abilify Mycite Kit patents expiration
ABILIFY MYCITE KIT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9125939 | November, 2016 | Terminated-Denied | Otsuka Pharmaceutical Co., Ltd. | Alkermes Pharma Ireland Limited |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 13 November, 2017
Treatment: Acute treatment of manic and mixed episodes associated with bipolar i disorder
Dosage: TABLET;ORAL
ABILIFY MYCITE KIT family patents
109. Tobi Podhaler patents expiration
TOBI PODHALER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10207066 | October, 2016 | Decision | Michael John Dunkley et al | |
| US10207066 | May, 2009 | Decision | Michael John Dunkley et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10207066 | MYLAN SPECIALITY LP | Aerosolization apparatus with capsule puncture alignment guide |
Nov, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 22, 2016 |
Drugs and Companies using TOBRAMYCIN ingredient
Market Authorisation Date: 22 March, 2013
Treatment: Treatment of cystic fibrosis patients with pseudomonas aeruginosa
Dosage: POWDER;INHALATION
TOBI PODHALER family patents
110. Toviaz patents expiration
TOVIAZ IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US6858650 | August, 2016 | FWD Entered | UCB Pharma GmbH | Alembic Pharmaceuticals Limited |
| US6858650 | August, 2016 | FWD Entered | UCB Pharma GmbH | Amerigen Pharmaceuticals Limited |
| US6858650 | August, 2016 | FWD Entered | UCB Pharma GmbH | Torrent Pharmaceuticals Limited |
| US6858650 | January, 2016 | FWD Entered | UCB Pharma GmbH | Mylan Pharmaceuticals Inc |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(1 year, 10 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-861) | Jun 17, 2024 |
| Pediatric Exclusivity(PED) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 31, 2013 |
Drugs and Companies using FESOTERODINE FUMARATE ingredient
NCE-1 date: 18 December, 2023
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
TOVIAZ family patents
111. Glyxambi patents expiration
GLYXAMBI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8673927 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US8846695 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US9173859 | August, 2016 | Terminated-Denied | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-739) | Dec 02, 2019 |
| New Combination(NC) | Jan 30, 2018 |
| M(M-258) | Jul 03, 2022 |
| New Chemical Entity Exclusivity(NCE) | Aug 01, 2019 |
| M(M-252) | Mar 30, 2023 |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient
NCE-1 date: 01 August, 2018
Market Authorisation Date: 30 January, 2015
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...
Dosage: TABLET;ORAL
GLYXAMBI family patents
112. Jentadueto patents expiration
JENTADUETO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8673927 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US8846695 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US9173859 | August, 2016 | Terminated-Denied | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-146) | Jul 30, 2017 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
| New Combination(NC) | Jan 30, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 30 January, 2012
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin
Dosage: TABLET;ORAL
JENTADUETO family patents
113. Jentadueto Xr patents expiration
JENTADUETO XR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8673927 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US8846695 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US9173859 | August, 2016 | Terminated-Denied | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
JENTADUETO XR family patents
114. Tradjenta patents expiration
TRADJENTA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8673927 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US8846695 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US8853156 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US9173859 | August, 2016 | Terminated-Denied | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US8846695 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor |
Jun, 2030
(6 years from now) | |
| US8853156 | BOEHRINGER INGELHEIM | Treatment for diabetes in patients inappropriate for metformin therapy |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-295) | Jun 20, 2026 |
| Pediatric Exclusivity(PED) | Dec 20, 2026 |
| M(M-252) | Mar 30, 2023 |
| M(M-258) | Jul 03, 2022 |
| M(M-121) | Aug 13, 2015 |
| New Chemical Entity Exclusivity(NCE) | May 02, 2016 |
| M(M-118) | Aug 13, 2015 |
Drugs and Companies using LINAGLIPTIN ingredient
NCE-1 date: 20 December, 2025
Market Authorisation Date: 02 May, 2011
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin; Method of treating typ...
Dosage: TABLET;ORAL
TRADJENTA family patents
115. Trijardy Xr patents expiration
TRIJARDY XR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8673927 | August, 2016 | Terminated-Adverse Judgment | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| US9173859 | August, 2016 | Terminated-Denied | Boehringer Ingelheim Pharmaceuticals Inc. | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8673927 | BOEHRINGER INGELHEIM | Uses of DPP-IV inhibitors |
May, 2027
(3 years from now) | |
| US9173859 | BOEHRINGER INGELHEIM | Uses of DPP IV inhibitors |
May, 2027
(3 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin
Dosage: TABLET, EXTENDED RELEASE;ORAL
TRIJARDY XR family patents
116. Stivarga patents expiration
STIVARGA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8637553 | July, 2016 | Terminated-Denied | Bayer HealthCare LLC | Fustibal LLC |
| US9957232 | November, 2015 | Decision | Alfons Grunenberg et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8637553 | BAYER HLTHCARE | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
Feb, 2031
(6 years from now) | |
| US9957232 | BAYER HLTHCARE | 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate |
Jul, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-139) | Apr 27, 2024 |
| New Indication(I-744) | Apr 27, 2020 |
| Orphan Drug Exclusivity(ODE-44) | Feb 25, 2020 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2017 |
| New Indication(I-667) | Feb 25, 2016 |
Drugs and Companies using REGORAFENIB ingredient
NCE-1 date: 27 September, 2016
Market Authorisation Date: 27 September, 2012
Treatment: NA
Dosage: TABLET;ORAL
STIVARGA family patents
117. Rasuvo patents expiration
RASUVO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8664231 | July, 2016 | FWD Entered | MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH | Koios Pharmaceuticals LLC |
| US8664231 | February, 2016 | Terminated-Settled | MEDAC GESELLSCHAFT FÜR KLINISCHE SPEZIALPRÄPARATE MBH | Frontier Therapeutics, LLC |
| US8664231 | July, 2014 | Terminated-Settled | Medac Gesellschaft Fur Klinische | Antares Pharma, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8664231 | MEDEXUS | Concentrated methotrexate solutions |
Jun, 2029
(5 years from now) | |
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 10 July, 2014
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION;SUBCUTANEOUS
RASUVO family patents
118. Alimta patents expiration
ALIMTA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7772209 | July, 2016 | FWD Entered | Eli Lilly and Company | Apotex Inc. |
| US7772209 | July, 2016 | FWD Entered | Eli Lilly and Company | Wockhardt Bio AG |
| US7772209 | July, 2016 | FWD Entered | Eli Lilly and Company | Apotex Inc. |
| US7772209 | July, 2016 | FWD Entered | Eli Lilly and Company | Teva Pharmaceuticals USA, Inc. |
| US7772209 | June, 2016 | FWD Entered | Eli Lilly and Company | Wockhardt Bio AG |
| US7772209 | December, 2015 | FWD Entered | Eli Lilly and Company | Sandoz Inc. |
| US7772209 | November, 2015 | FWD Entered | Eli Lilly and Company | Neptune Generics, LLC |
| US7772209 | June, 2013 | Terminated-Denied | Eli Lilly and Company | Accord Healthcare, Inc., USA |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7772209 | LILLY | Antifolate combination therapies |
Nov, 2021
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-571) | Sep 26, 2011 |
| New Indication(I-601) | Jul 02, 2012 |
| M(M-122) | Oct 17, 2015 |
| M(M-61) | Mar 17, 2014 |
| Pediatric Exclusivity(PED) | Sep 17, 2014 |
Drugs and Companies using PEMETREXED DISODIUM ingredient
Market Authorisation Date: 07 September, 2007
Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration
Dosage: POWDER;INTRAVENOUS
ALIMTA family patents
119. Pemfexy patents expiration
PEMFEXY IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7772209 | July, 2016 | FWD Entered | Eli Lilly and Company | Apotex Inc. |
| US7772209 | July, 2016 | FWD Entered | Eli Lilly and Company | Wockhardt Bio AG |
| US7772209 | July, 2016 | FWD Entered | Eli Lilly and Company | Apotex Inc. |
| US7772209 | July, 2016 | FWD Entered | Eli Lilly and Company | Teva Pharmaceuticals USA, Inc. |
| US7772209 | June, 2016 | FWD Entered | Eli Lilly and Company | Wockhardt Bio AG |
| US7772209 | December, 2015 | FWD Entered | Eli Lilly and Company | Sandoz Inc. |
| US7772209 | November, 2015 | FWD Entered | Eli Lilly and Company | Neptune Generics, LLC |
| US7772209 | June, 2013 | Terminated-Denied | Eli Lilly and Company | Accord Healthcare, Inc., USA |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7772209 | EAGLE PHARMS | Antifolate combination therapies |
May, 2022
(1 year, 11 months ago) | |
Drugs and Companies using PEMETREXED ingredient
Market Authorisation Date: 08 February, 2020
Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with non-squamous non-small cell lung cancer
Dosage: SOLUTION;INTRAVENOUS
PEMFEXY family patents
120. Apriso patents expiration
APRISO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8865688 | July, 2016 | Terminated-Other | ||
| US8865688 | July, 2016 | Terminated-Other | ||
| US8865688 | December, 2015 | FWD Entered | SALIX PHARMACEUTICALS, LTD. | GeneriCo, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8865688 | SALIX | Compositions and methods for treatment of bowel diseases with granulated mesalamine |
May, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 31, 2011 |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 31 October, 2008
Treatment: For the maintenance of remission of ulcerative colitis
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
APRISO family patents
121. Vimpat patents expiration
VIMPAT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| USRE38551 | June, 2016 | Terminated-Denied | Research Corporation Technologies, Inc. | Mylan Pharmaceuticals Inc. |
| USRE38551 | June, 2016 | FWD Entered | Research Corporation Technologies, Inc. | Alembic Pharmaceuticals, Ltd. |
| USRE38551 | June, 2016 | FWD Entered | Research Corporation Technologies, Inc. | Breckenridge Phamaceutical, Inc. |
| USRE38551 | May, 2016 | FWD Entered | Research Corporation Technologies, Inc. | Mylan Pharmaceuticals Inc. |
| USRE38551 | November, 2015 | FWD Entered | Research Corporation Technologies, Inc. | Argentum Pharmaceuticals LLC |
| USRE38551 | July, 2014 | Terminated-Denied | Research Corporation Technologies, Inc. | ACTAVIS, INC. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE38551 | UCB INC | Anticonvulsant enantiomeric amino acid derivatives |
Mar, 2022
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-188) | Apr 28, 2026 |
| New Patient Population(NPP) | Oct 14, 2024 |
| New Dosing Schedule(D-144) | Aug 29, 2017 |
| New Indication(I-696) | Aug 29, 2017 |
| New Dosing Schedule(D-143) | Aug 29, 2017 |
| New Indication(I-878) | Nov 16, 2023 |
| New Chemical Entity Exclusivity(NCE) | Oct 28, 2013 |
Drugs and Companies using LACOSAMIDE ingredient
NCE-1 date: 28 October, 2012
Market Authorisation Date: 28 October, 2008
Treatment: Method of treating, as adjunctive therapy, partial-onset seizures in a patient with epilepsy aged 17 years and older when oral treatment is temporarily not feasible
Dosage: TABLET;ORAL; SOLUTION;ORAL; SOLUTION;INTRAVENOUS
VIMPAT family patents
122. Bepreve patents expiration
BEPREVE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8877168 | June, 2016 | Terminated-Settled | Senju Pharmaceuticals Co., Ltd. | Mylan Pharmaceuticals, Inc. |
| US8784789 | February, 2016 | Terminated-Settled | Senju Pharmaceutical Co. Ltd. | Mylan Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8877168 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jul, 2023
(9 months ago) | |
| US8784789 | BAUSCH AND LOMB INC | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
Jan, 2025
(8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 08, 2014 |
Drugs and Companies using BEPOTASTINE BESILATE ingredient
NCE-1 date: 08 September, 2013
Market Authorisation Date: 08 September, 2009
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
BEPREVE family patents
123. Kombiglyze Xr patents expiration
KOMBIGLYZE XR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| USRE44186 | June, 2016 | FWD Entered | ASTRAZENECA AB | Aurobindo Pharma U.S.A., Inc. |
| USRE44186 | June, 2016 | FWD Entered | AstraZeneca AB | Amneal Pharmaceuticals LLC |
| USRE44186 | June, 2016 | FWD Entered | AstraZeneca AB | Teva Pharmaceuticals USA Inc. |
| USRE44186 | May, 2016 | FWD Entered | AstraZeneca AB | Wockhardt Bio AG |
| USRE44186 | June, 2015 | FWD Entered | AstraZeneca AB | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 05 November, 2010
Treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate
Dosage: TABLET, EXTENDED RELEASE;ORAL
KOMBIGLYZE XR family patents
124. Onglyza patents expiration
ONGLYZA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| USRE44186 | June, 2016 | FWD Entered | ASTRAZENECA AB | Aurobindo Pharma U.S.A., Inc. |
| USRE44186 | June, 2016 | FWD Entered | AstraZeneca AB | Amneal Pharmaceuticals LLC |
| USRE44186 | June, 2016 | FWD Entered | AstraZeneca AB | Teva Pharmaceuticals USA Inc. |
| USRE44186 | May, 2016 | FWD Entered | AstraZeneca AB | Wockhardt Bio AG |
| USRE44186 | June, 2015 | FWD Entered | AstraZeneca AB | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-134) | May 24, 2016 |
| M(M-175) | Apr 05, 2019 |
| M(M-198) | Feb 27, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2014 |
| M(M-108) | Dec 16, 2014 |
Drugs and Companies using SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 31 July, 2013
Market Authorisation Date: 31 July, 2009
Treatment: Method for treating type ii diabetes by administering saxagliptin
Dosage: TABLET;ORAL
ONGLYZA family patents
125. Qtern patents expiration
QTERN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| USRE44186 | June, 2016 | FWD Entered | ASTRAZENECA AB | Aurobindo Pharma U.S.A., Inc. |
| USRE44186 | June, 2016 | FWD Entered | AstraZeneca AB | Amneal Pharmaceuticals LLC |
| USRE44186 | June, 2016 | FWD Entered | AstraZeneca AB | Teva Pharmaceuticals USA Inc. |
| USRE44186 | May, 2016 | FWD Entered | AstraZeneca AB | Wockhardt Bio AG |
| USRE44186 | June, 2015 | FWD Entered | AstraZeneca AB | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-175) | Apr 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jan 08, 2019 |
| New Combination(NC) | Feb 27, 2020 |
| New Strength(NS) | May 02, 2022 |
| New Indication(I-804) | May 02, 2022 |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
NCE-1 date: 08 January, 2018
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET;ORAL
QTERN family patents
126. Qternmet Xr patents expiration
QTERNMET XR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| USRE44186 | June, 2016 | FWD Entered | ASTRAZENECA AB | Aurobindo Pharma U.S.A., Inc. |
| USRE44186 | June, 2016 | FWD Entered | AstraZeneca AB | Amneal Pharmaceuticals LLC |
| USRE44186 | June, 2016 | FWD Entered | AstraZeneca AB | Teva Pharmaceuticals USA Inc. |
| USRE44186 | May, 2016 | FWD Entered | AstraZeneca AB | Wockhardt Bio AG |
| USRE44186 | June, 2015 | FWD Entered | AstraZeneca AB | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 02, 2022 |
Market Authorisation Date: 02 May, 2019
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE;ORAL
QTERNMET XR family patents
127. Inomax patents expiration
INOMAX IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8282966 | March, 2016 | Terminated-Denied | Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8795741 | March, 2016 | Terminated-Denied | Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8293284 | March, 2016 | Terminated-Denied | Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8431163 | March, 2016 | Terminated-Denied | Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8846112 | March, 2016 | Terminated-Denied | Mallinckrodt Hospital Products IP Ltd. | Praxair Distribution, Inc. |
| US8573209 | March, 2015 | FWD Entered | INO THERAPEUTICS LLC | Praxair Distribution, Inc. |
| US8776794 | March, 2015 | FWD Entered | INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8573210 | March, 2015 | FWD Entered | INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8776795 | March, 2015 | FWD Entered | INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8291904 | March, 2015 | FWD Entered | INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8282966 | January, 2015 | Terminated-Denied | INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8293284 | January, 2015 | Terminated-Denied | INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8795741 | January, 2015 | Terminated-Denied | INO Therapeutics LLC | Praxair Distribution, Inc. |
| US8846112 | January, 2015 | FWD Entered | INO THERAPEUTICS LLC | Praxair Distribution, Inc. |
| US8431163 | January, 2015 | Terminated-Denied | INO THERAPEUTICS LLC | Praxair Distribution, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431163 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Jun, 2029
(5 years from now) | |
| US8282966 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Jun, 2029
(5 years from now) | |
| US8293284 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Jun, 2029
(5 years from now) | |
| US8795741 | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Jun, 2029
(5 years from now) | |
| US8846112 | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Jun, 2029
(5 years from now) | |
| US8776795 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US8291904 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| US8776794 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US8573210 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(6 years from now) | |
| US8573209 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-167) | Oct 09, 2018 |
| M(M-132) | Dec 21, 2013 |
| Pediatric Exclusivity(PED) | Jun 21, 2014 |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide; A method of providing a predetermined concentration of nitric oxide to a patient; A method ...
Dosage: GAS;INHALATION
INOMAX family patents
128. Jevtana Kit patents expiration
JEVTANA KIT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8927592 | March, 2016 | FWD Entered | AVENTIS PHARMA S.A. | Mylan Laboratories Limited |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8927592 | SANOFI AVENTIS US | Antitumoral use of cabazitaxel |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-209) | Sep 14, 2020 |
| M(M-201) | May 17, 2020 |
| M(M-128) | Dec 18, 2023 |
| Pediatric Exclusivity(PED) | Nov 17, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jun 17, 2015 |
Drugs and Companies using CABAZITAXEL ingredient
NCE-1 date: 18 November, 2019
Market Authorisation Date: 17 June, 2010
Treatment: Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antih...
Dosage: SOLUTION;INTRAVENOUS
JEVTANA KIT family patents
129. Xyrem patents expiration
XYREM IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9050302 | March, 2016 | Terminated-Denied | Jazz Pharmaceuticals Ireland Limited | RANBAXY INC |
| US8772306 | February, 2016 | Terminated-Denied | Jazz Pharmaceutical, Inc. | Amneal Pharmaceuticals LLC |
| US8772306 | October, 2015 | Terminated-Settled | Jazz Pharmaceutical, Inc. | Ranbaxy, Inc. |
| US8772306 | October, 2015 | Terminated-Denied | Jazz Pharmaceutical, Inc. | Par Pharmaceutical, Inc. |
| US8731963 | September, 2015 | Final Written Decision | Jazz Pharmaceuticals, Inc. | Par Pharmaceutical, Inc. et al. |
| US7668730 | August, 2015 | FWD Entered | Jazz Pharmaceuticals, Inc. | Wockhardt Bio AG |
| US7668730 | January, 2015 | Final Written Decision | Jazz Pharmaceuticals, Inc. | PAR PHARMACEUTICAL, INC. et al. |
| US7668730 | July, 2014 | Terminated-Denied | Jazz Pharmaceuticals, Inc. | PAR PHARMACEUTICAL, INC. |
| US7668730 | May, 2008 | Decision | Dayton T. Reardan et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8731963 | JAZZ PHARMS | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
| US7668730 | JAZZ PHARMS | Sensitive drug distribution system and method |
Jun, 2024
(a month from now) | |
| US9050302 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US8772306 | JAZZ PHARMS | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-231) | Oct 26, 2025 |
| Pediatric Exclusivity(PED) | Apr 26, 2026 |
| New Patient Population(NPP) | Oct 26, 2021 |
| Orphan Drug Exclusivity(ODE) | Nov 18, 2012 |
Drugs and Companies using SODIUM OXYBATE ingredient
Market Authorisation Date: 17 July, 2002
Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy pa...
Dosage: SOLUTION;ORAL
XYREM family patents
130. Xywav patents expiration
XYWAV IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9050302 | March, 2016 | Terminated-Denied | Jazz Pharmaceuticals Ireland Limited | RANBAXY INC |
| US8772306 | February, 2016 | Terminated-Denied | Jazz Pharmaceutical, Inc. | Amneal Pharmaceuticals LLC |
| US8772306 | October, 2015 | Terminated-Settled | Jazz Pharmaceutical, Inc. | Ranbaxy, Inc. |
| US8772306 | October, 2015 | Terminated-Denied | Jazz Pharmaceutical, Inc. | Par Pharmaceutical, Inc. |
| US8731963 | September, 2015 | Final Written Decision | Jazz Pharmaceuticals, Inc. | Par Pharmaceutical, Inc. et al. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8731963 | JAZZ | Sensitive drug distribution system and method |
Dec, 2022
(1 year, 4 months ago) | |
| US9050302 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| US8772306 | JAZZ | Method of administration of gamma hydroxybutyrate with monocarboxylate transporters |
Mar, 2033
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-361) | Jul 21, 2027 |
| New Indication(I-870) | Aug 12, 2024 |
| Orphan Drug Exclusivity(ODE-369) | Aug 12, 2028 |
| Orphan Drug Exclusivity(ODE-231) | Jul 21, 2027 |
| New Product(NP) | Jul 21, 2023 |
Market Authorisation Date: 21 July, 2020
Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy pa...
Dosage: SOLUTION;ORAL
XYWAV family patents
131. Fanapt patents expiration
FANAPT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9138432 | February, 2016 | Terminated-Denied | Vanda Pharmaceuticals Inc. | Roxane Laboratories, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9138432 | VANDA PHARMS INC | Methods for the administration of iloperidone |
Sep, 2025
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-180) | May 26, 2019 |
| New Chemical Entity Exclusivity(NCE) | May 06, 2014 |
Drugs and Companies using ILOPERIDONE ingredient
NCE-1 date: 06 May, 2013
Market Authorisation Date: 06 May, 2009
Treatment: Method of treating schizophrenia by administering iloperidone to a patient by reducing the dose in patients who are being treated with fluoxetine
Dosage: TABLET;ORAL
FANAPT family patents
132. Aloxi patents expiration
ALOXI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9173942 | February, 2016 | Terminated-Denied | Helsinn Healthcare S.A. | Dr. Reddy's Laboratories, Ltd |
| US8729094 | July, 2015 | Terminated-Denied | Helsinn Healthcare S.A. | Dr. Reddy's Laboratories, Ltd |
| US8729094 | July, 2015 | Terminated-Denied | Helsinn Healthcare S.A. | Dr. Reddy's Laboratories, Ltd. |
| US8598219 | September, 2014 | Terminated-Denied | Helsinn Healthcare S.A. | Accord Healthcare, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8598219 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US8729094 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| US9173942 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-684) | May 27, 2017 |
| M(M-136) | May 27, 2017 |
| Pediatric Exclusivity(PED) | Nov 27, 2017 |
Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 29 February, 2008
Treatment: Prevention of chemotherapy-induced nausea and vomiting
Dosage: INJECTABLE;INTRAVENOUS
ALOXI family patents
133. Nucynta patents expiration
NUCYNTA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7994364 | January, 2016 | Terminated-Denied | Gruenenthal GmbH | Rosellini Scientific, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 03, 2026 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 20 November, 2008
Treatment: Management of moderate to severe acute pain
Dosage: TABLET;ORAL; SOLUTION;ORAL
NUCYNTA family patents
134. Nucynta Er patents expiration
NUCYNTA ER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7994364 | January, 2016 | Terminated-Denied | Gruenenthal GmbH | Rosellini Scientific, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(1 year, 1 month from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 25, 2014 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Indication(I-656) | Aug 28, 2015 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 25 August, 2011
Treatment: Management of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE;ORAL
NUCYNTA ER family patents
135. Zorvolex patents expiration
ZORVOLEX IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8999387 | December, 2015 | Terminated-Denied | iCeutica Pty Ltd. | Lupin Pharmaceuticals, Inc. |
| US9017721 | December, 2015 | Terminated-Denied | iCeutica Pty Ltd. | Lupin Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8999387 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
| US9017721 | ZYLA | Formulation of diclofenac |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-692) | Aug 22, 2017 |
| New Product(NP) | Oct 18, 2016 |
Drugs and Companies using DICLOFENAC ingredient
Market Authorisation Date: 18 October, 2013
Treatment: Treatment of pain
Dosage: CAPSULE;ORAL
ZORVOLEX family patents
136. Diprivan patents expiration
DIPRIVAN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8476010 | November, 2015 | FWD Entered | Fresenius Kabi USA, LLC | J Kyle Bass |
| US8476010 | February, 2015 | Terminated-Denied | Fresenius Kabi USA, LLC | Dr. Reddy's Laboratories, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8476010 | FRESENIUS KABI USA | Propofol formulations with non-reactive container closures |
Dec, 2024
(6 months from now) | |
Drugs and Companies using PROPOFOL ingredient
Market Authorisation Date: 02 October, 1989
Treatment: NA
Dosage: INJECTABLE;INJECTION
DIPRIVAN family patents
137. Suprenza patents expiration
SUPRENZA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8440170 | November, 2015 | Terminated-Adverse Judgment | ALPEX PHARMA | Erich Spangenberg |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8440170 | CITIUS PHARMS | Orally disintegrating tablets with speckled appearance |
Mar, 2029
(4 years from now) | |
Drugs and Companies using PHENTERMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 13 June, 2011
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
SUPRENZA family patents
138. Treximet patents expiration
TREXIMET IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7332183 | November, 2015 | Terminated-Denied | POZEN Inc. | Graybar Pharmaceuticals, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7332183 | CURRAX | Multilayer dosage forms containing NSAIDs and triptans |
Oct, 2025
(1 year, 4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 14, 2018 |
| Pediatric Exclusivity(PED) | Nov 14, 2018 |
Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 14 May, 2015
Treatment: Acute treatment of migraine
Dosage: TABLET;ORAL
TREXIMET family patents
139. Prolensa patents expiration
PROLENSA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8754131 | November, 2015 | FWD Entered | SENJU PHARMACEUTICAL CO., LTD. | InnoPharma Licensing, Inc. |
| US8871813 | November, 2015 | FWD Entered | SENJU PHARMACEUTICAL CO., LTD. | InnoPharma Licensing, Inc. |
| US8927606 | November, 2015 | FWD Entered | SENJU PHARMACEUTICAL CO., LTD. | InnoPharma Licensing, Inc. |
| US8129431 | September, 2015 | FWD Entered | SENJU PHARMACEUTICAL CO., LTD. | Lupin Ltd. |
| US8669290 | April, 2015 | FWD Entered | SENJU PHARMACEUTICAL CO., LTD. | Lupin Ltd. |
| US8754131 | April, 2015 | FWD Entered | SENJU PHARMACEUTICAL CO., LTD. | Lupin Ltd. |
| US8871813 | April, 2015 | FWD Entered | SENJU PHARMACEUTICAL CO., LTD. | Lupin Ltd. |
| US8927606 | April, 2015 | FWD Entered | Senju Pharmaceutical Co., Ltd. | Lupin Ltd. |
| US8129431 | March, 2015 | FWD Entered | Senju Pharmaceutical Co., Ltd. | InnoPharma, Licensing, Inc. |
| US8669290 | March, 2015 | FWD Entered | SENJU PHARMACEUTICAL CO., LTD. | InnoPharma Licensing, Inc. |
| US8129431 | June, 2014 | Terminated-Settled | Senju Pharmaceutical Co., Ltd. | Metrics, Inc. c/o Duane Morris LLP |
| US8669290 | June, 2014 | Terminated-Settled | SENJU PHARMACEUTICAL CO., LTD. | Metrics, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8129431 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Sep, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8927606 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8754131 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8871813 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| US8669290 | BAUSCH AND LOMB | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid |
Jan, 2024
(3 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2016 |
Drugs and Companies using BROMFENAC SODIUM ingredient
Market Authorisation Date: 05 April, 2013
Treatment: Method of treating ocular inflammation
Dosage: SOLUTION/DROPS;OPHTHALMIC
PROLENSA family patents
140. Treanda patents expiration
TREANDA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8895756 | November, 2015 | Terminated-Settled | Cephalon, Inc. | Fresenius Kabi USA, LLC |
| US8791270 | October, 2015 | Terminated-Settled | Cephalon, Inc. | Fresenius Kabi USA, LLC |
| US8791270 | October, 2015 | Terminated-Denied | Cephalon, Inc. | AGILA SPECIALTIES INC. |
| US8436190 | December, 2014 | Terminated-Settled | Cephalon, Inc. | AGILA SPECIALTIES INC. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
| US8895756 | CEPHALON | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
| US8436190 | CEPHALON | Bendamustine pharmaceutical compositions |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-580) | Oct 31, 2011 |
| Orphan Drug Exclusivity(ODE) | Mar 20, 2015 |
| Pediatric Exclusivity(PED) | Sep 20, 2013 |
| ODE*(ODE*) | Dec 07, 2022 |
| New Chemical Entity Exclusivity(NCE) | Mar 20, 2013 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
NCE-1 date: 02 May, 2015
Market Authorisation Date: 01 May, 2009
Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma
Dosage: SOLUTION;IV (INFUSION); POWDER;IV (INFUSION)
TREANDA family patents
141. Belrapzo patents expiration
BELRAPZO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8791270 | October, 2015 | Terminated-Settled | Cephalon, Inc. | Fresenius Kabi USA, LLC |
| US8791270 | October, 2015 | Terminated-Denied | Cephalon, Inc. | AGILA SPECIALTIES INC. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| ODE*(ODE*) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 May, 2018
Treatment: For the treatment of patients with indolent b-cell non-hodgkin lymphoma
Dosage: SOLUTION;INTRAVENOUS
BELRAPZO family patents
142. Bendeka patents expiration
BENDEKA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8791270 | October, 2015 | Terminated-Settled | Cephalon, Inc. | Fresenius Kabi USA, LLC |
| US8791270 | October, 2015 | Terminated-Denied | Cephalon, Inc. | AGILA SPECIALTIES INC. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8791270 | EAGLE PHARMS | Bendamustine pharmaceutical compositions |
Jan, 2026
(1 year, 8 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-179) | Dec 07, 2022 |
Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 December, 2015
Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma
Dosage: SOLUTION;IV (INFUSION)
BENDEKA family patents
143. Sensipar patents expiration
SENSIPAR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7829595 | October, 2015 | Terminated-Denied | ||
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7829595 | AMGEN | Rapid dissolution formulation of a calcium receptor-active compound |
Sep, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-200) | May 23, 2020 |
| Orphan Drug Exclusivity(ODE-78) | Nov 21, 2021 |
| Orphan Drug Exclusivity(ODE-8) | Feb 25, 2018 |
| M(M-101) | Feb 25, 2014 |
| New Indication(I-634) | Feb 25, 2014 |
| Orphan Drug Exclusivity(ODE) | Feb 25, 2018 |
Drugs and Companies using CINACALCET HYDROCHLORIDE ingredient
Market Authorisation Date: 08 March, 2004
Treatment: Method of treating hyperparathyroidism; Method of treating hypercalcemia
Dosage: TABLET;ORAL
SENSIPAR family patents
144. Movantik patents expiration
MOVANTIK IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7786133 | October, 2015 | Terminated-Denied | NEKTAR THERAPEUTICS | Neptune Generics, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7786133 | VALINOR | Chemically modified small molecules |
Sep, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 16, 2019 |
Drugs and Companies using NALOXEGOL OXALATE ingredient
NCE-1 date: 16 September, 2018
Market Authorisation Date: 16 September, 2014
Treatment: NA
Dosage: TABLET;ORAL
MOVANTIK family patents
145. Veregen patents expiration
VEREGEN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9770406 | September, 2015 | Decision | Yunik Chang et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9770406 | ANI PHARMS | Medicament for the treatment of viral skin and tumour diseases |
Jul, 2025
(1 year, 2 months from now) | |
Drugs and Companies using SINECATECHINS ingredient
Market Authorisation Date: 31 October, 2006
Treatment: Treatment of genital warts
Dosage: OINTMENT;TOPICAL
VEREGEN family patents
146. Juxtapid patents expiration
JUXTAPID IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7932268 | August, 2015 | FWD Entered | The Trustees of the University of Pennsylvania) | Coalition for Affordable Drugs VIII |
| US8618135 | August, 2015 | FWD Entered | The Trustees of the University of Pennsylvania | COALITION FOR AFFORDABLE DRUGS VIII, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8618135 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Mar, 2025
(10 months from now) | |
| US7932268 | CHIESI | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
| Orphan Drug Exclusivity(ODE-36) | Dec 21, 2019 |
Drugs and Companies using LOMITAPIDE MESYLATE ingredient
NCE-1 date: 21 December, 2016
Market Authorisation Date: 21 December, 2012
Treatment: A dosing regimen for the treatment of hypercholesterolemia and hyperlipidemia in patients with homozygous familial hypercholesterolemia using at least three step-wise increasing doses
Dosage: CAPSULE;ORAL
JUXTAPID family patents
147. Subsys patents expiration
SUBSYS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8486972 | August, 2015 | Terminated-Denied | Insys Pharma, Inc. | Coalition For Affordable Drugs XI LLC |
| US8835459 | August, 2015 | Terminated-Denied | Insys Pharma, Inc. | Coalition For Affordable Drugs XI LLC |
| US8835460 | August, 2015 | Terminated-Denied | Insys Pharma, Inc. | Coalition For Affordable Drugs XI LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8835460 | BTCP PHARMA | Sublingual fentanyl spray and methods of treating pain |
Jan, 2027
(2 years from now) | |
| US8835459 | BTCP PHARMA | Sublingual fentanyl spray |
Jan, 2027
(2 years from now) | |
| US8486972 | BTCP PHARMA | Sublingual fentanyl spray |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 04, 2015 |
Drugs and Companies using FENTANYL ingredient
Market Authorisation Date: 04 January, 2012
Treatment: Treatment of pain
Dosage: SPRAY;SUBLINGUAL
SUBSYS family patents
148. Oracea patents expiration
ORACEA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8603506 | August, 2015 | Terminated-Denied | GALDERMA LABORATORIES, INC. | Dr. Reddy’s Laboratories, Ltd. |
| US8206740 | June, 2013 | FWD Entered | ||
| US8394405 | June, 2013 | FWD Entered | Supernus Pharmaceuticals, Inc. | Amneal Pharamceuticals, LLC |
| US8394406 | June, 2013 | FWD Entered | ||
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8603506 | GALDERMA LABS LP | Methods of treating acne |
Apr, 2022
(2 years ago) | |
| US8394406 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(26 days ago) | |
| US8394405 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Apr, 2024
(26 days ago) | |
| US8206740 | GALDERMA LABS LP | Once daily formulations of tetracyclines |
Dec, 2025
(1 year, 7 months from now) | |
Drugs and Companies using DOXYCYCLINE ingredient
Market Authorisation Date: 26 May, 2006
Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea
Dosage: CAPSULE;ORAL
ORACEA family patents
149. Injectafer patents expiration
INJECTAFER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7754702 | June, 2015 | FWD Entered | Luitpold Pharmaceuticals, Inc. | Pharmacosmos A/S |
| US8895612 | June, 2015 | Terminated-Denied | Luitpold Pharmaceuticals, Inc. | Pharmacosmos A/S |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8895612 | AM REGENT | Methods and compositions for administration of iron |
Jan, 2027
(2 years from now) | |
| US7754702 | AM REGENT | Methods and compositions for administration of iron |
Feb, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-915) | May 31, 2026 |
| New Patient Population(NPP) | Nov 19, 2024 |
| New Strength(NS) | Apr 28, 2024 |
| New Product(NP) | Jul 25, 2016 |
Drugs and Companies using FERRIC CARBOXYMALTOSE ingredient
Market Authorisation Date: 28 April, 2021
Treatment: Method to treat ida in adults & pediatric patients 1 yr & older with intolerance or unsatisfactory response to oral iron & weighing at least 40 kg by administering iv at least about 0.6 g of iron as f...
Dosage: SOLUTION;INTRAVENOUS
INJECTAFER family patents
150. Yosprala patents expiration
YOSPRALA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US6926907 | May, 2015 | Terminated-Denied | POZEN Inc. | Coalition for Affordable Drugs VII LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6926907 | GENUS LIFESCIENCES | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb, 2023
(1 year, 2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Sep 14, 2019 |
Drugs and Companies using ASPIRIN; OMEPRAZOLE ingredient
Market Authorisation Date: 14 September, 2016
Treatment: Treatment or secondary prevention of cardiovascular disease, cardiovascular events, or cerebrovascular events and risk-reduction of aspirin-associated gastric ulcers
Dosage: TABLET, DELAYED RELEASE;ORAL
YOSPRALA family patents
151. Phenylephrine Hydrochloride patents expiration
PHENYLEPHRINE HYDROCHLORIDE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8859623 | May, 2015 | FWD Entered | Paragon BioTeck, Inc. | Altaire Pharmaceuticals, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859623 | PARAGON BIOTECK | Methods and compositions of stable phenylephrine formulations |
Nov, 2033
(9 years from now) | |
Drugs and Companies using PHENYLEPHRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 March, 2013
Treatment: Dilation of the pupil
Dosage: SOLUTION/DROPS;OPHTHALMIC
PHENYLEPHRINE HYDROCHLORIDE family patents
152. Gattex Kit patents expiration
GATTEX KIT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7056886 | April, 2015 | FWD Entered | NPS Pharmaceuticals, Inc. | Coalition for Affordable Drugs II, LLC |
| US7056886 | April, 2015 | FWD Entered | NPS Pharmaceuticals, Inc. | Coalition for Affordable Drugs II LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7056886 | TAKEDA PHARMS USA | GLP-2 formulations |
Sep, 2022
(1 year, 7 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-240) | May 16, 2026 |
| Orphan Drug Exclusivity(ODE-37) | Dec 21, 2019 |
| Pediatric Exclusivity(PED) | Jun 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2019 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2017 |
Drugs and Companies using TEDUGLUTIDE ingredient
NCE-1 date: 22 June, 2019
Market Authorisation Date: 21 December, 2012
Treatment: Treatment of adult patients with short bowel syndrome who are dependent on parenteral support
Dosage: POWDER;SUBCUTANEOUS
GATTEX KIT family patents
153. Nocdurna patents expiration
NOCDURNA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9974826 | April, 2015 | Decision | Bjarke Mimer Klein et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9974826 | FERRING PHARMS INC | Methods comprising desmopressin |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 21, 2021 |
Drugs and Companies using DESMOPRESSIN ACETATE ingredient
Market Authorisation Date: 21 June, 2018
Treatment: Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration
Dosage: TABLET;SUBLINGUAL
NOCDURNA family patents
154. Prezcobix patents expiration
PREZCOBIX IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8518987 | April, 2015 | Terminated-Denied | Janssen Sciences Ireland UC | Lupin Limited |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
Drugs and Companies using COBICISTAT; DARUNAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 29 January, 2015
Treatment: NA
Dosage: TABLET;ORAL
PREZCOBIX family patents
155. Prezista patents expiration
PREZISTA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8518987 | April, 2015 | Terminated-Denied | Janssen Sciences Ireland UC | Lupin Limited |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-119) | Dec 18, 2011 |
| New Strength(NS) | Dec 18, 2011 |
| New Indication(I-578) | Oct 21, 2011 |
| New Dosing Schedule(D-118) | Oct 21, 2011 |
| New Dosing Schedule(D-135) | Feb 01, 2016 |
| New Patient Population(NPP) | Dec 16, 2014 |
| Pediatric Exclusivity(PED) | Jun 13, 2014 |
| New Dosing Schedule(D-129) | Dec 13, 2013 |
Drugs and Companies using DARUNAVIR ingredient
Market Authorisation Date: 18 December, 2008
Treatment: NA
Dosage: TABLET;ORAL; SUSPENSION;ORAL
PREZISTA family patents
156. Symtuza patents expiration
SYMTUZA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8518987 | April, 2015 | Terminated-Denied | Janssen Sciences Ireland UC | Lupin Limited |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8518987 | JANSSEN PRODS | Pseudopolymorphic forms of a HIV protease inhibitor |
Feb, 2024
(2 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Combination(NC) | Jul 17, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 17 July, 2018
Treatment: NA
Dosage: TABLET;ORAL
SYMTUZA family patents
157. Tygacil patents expiration
TYGACIL IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7879828 | March, 2015 | Terminated-Denied | Wyeth LLC | Apotex Inc. |
| US7879828 | August, 2014 | Terminated-Denied | Wyeth LLC | Initiative for Responsibility in Drug Pricing LLC |
| US7879828 | November, 2013 | FWD Entered | Wyeth LLC | Apotex Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7879828 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Feb, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-587) | Mar 20, 2012 |
| New Indication(I-588) | Mar 20, 2012 |
| New Indication(I-586) | Mar 20, 2012 |
Drugs and Companies using TIGECYCLINE ingredient
Market Authorisation Date: 15 June, 2005
Treatment: NA
Dosage: POWDER;INTRAVENOUS
TYGACIL family patents
158. Combigan patents expiration
COMBIGAN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7030149 | March, 2015 | Terminated-Denied | Allergan Sales, LLC | Ferrum Ferro Capital, LLC |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7030149 | ABBVIE | Combination of brimonidine timolol for topical ophthalmic use |
Apr, 2022
(2 years ago) | |
Drugs and Companies using BRIMONIDINE TARTRATE; TIMOLOL MALEATE ingredient
Market Authorisation Date: 30 October, 2007
Treatment: Reduction of elevated intraocular pressure (iop) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled iop. dose is one drop of ...
Dosage: SOLUTION/DROPS;OPHTHALMIC
COMBIGAN family patents
159. Fabior patents expiration
FABIOR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10688071 | February, 2015 | Decision | Leon LOUPENOK | |
| US10568859 | April, 2014 | Decision | Leon LOUPENOK | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10568859 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
| US10688071 | MAYNE PHARMA | Topical foam composition |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | May 11, 2015 |
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 11 May, 2012
Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older
Dosage: AEROSOL, FOAM;TOPICAL
FABIOR family patents
160. Lo Loestrin Fe patents expiration
LO LOESTRIN FE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7704984 | February, 2015 | Terminated-Denied | Warner Chilcott Company, LLC | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 21, 2013 |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 21 October, 2010
Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
LO LOESTRIN FE family patents
161. Lo Minastrin Fe patents expiration
LO MINASTRIN FE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7704984 | February, 2015 | Terminated-Denied | Warner Chilcott Company, LLC | Mylan Pharmaceuticals Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(4 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 24 July, 2013
Treatment: Prevention of pregnancy
Dosage: TABLET, CHEWABLE, TABLET;ORAL
LO MINASTRIN FE family patents
162. Carnexiv patents expiration
CARNEXIV IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9770407 | December, 2014 | Decision | Lundbeck Pharmaceuticals LLC | |
| US9629797 | July, 2014 | Decision | James Cloyd et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629797 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(4 years from now) | |
| US9770407 | LUNDBECK PHARMS LLC | Parenteral carbamazepine formulation |
Nov, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Oct 07, 2023 |
| Orphan Drug Exclusivity(ODE-124) | Oct 07, 2023 |
Drugs and Companies using CARBAMAZEPINE ingredient
Market Authorisation Date: 07 October, 2016
Treatment: Replacement therapy for oral carbamazepine in adults with mixed seizure patterns that include partial seizures with complex symptomatology, generalized tonic-clonic seizures, or other partial or gener...
Dosage: SOLUTION;INTRAVENOUS
CARNEXIV family patents
163. Namenda Xr patents expiration
NAMENDA XR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8362085 | December, 2014 | Terminated-Denied | Adamas Pharmaceuticals, Inc. | Ranbaxy, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-138) | Jul 03, 2017 |
| Pediatric Exclusivity(PED) | Jan 03, 2018 |
| New Dosage Form(NDF) | Jun 21, 2013 |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 June, 2010
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
NAMENDA XR family patents
164. Namzaric patents expiration
NAMZARIC IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8362085 | December, 2014 | Terminated-Denied | Adamas Pharmaceuticals, Inc. | Ranbaxy, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8362085 | ABBVIE | Method for administering an NMDA receptor antagonist to a subject |
Nov, 2025
(1 year, 6 months from now) | |
Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 July, 2016
Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC family patents
165. Cardene In 0.83% Sodium Chloride In Plastic Container patents expiration
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7612102 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| US7659291 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| US8455524 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents
166. Cardene In 0.86% Sodium Chloride In Plastic Container patents expiration
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7612102 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| US7659291 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| US8455524 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER family patents
167. Cardene In 4.8% Dextrose In Plastic Container patents expiration
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7612102 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| US7659291 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| US8455524 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER family patents
168. Cardene In 5.0% Dextrose In Plastic Container patents expiration
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7612102 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| US7659291 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| US8455524 | October, 2014 | Terminated-Denied | EKR Therapeutics, LLC | Sandoz Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8455524 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7659291 | CHIESI | Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions |
Apr, 2027
(2 years from now) | |
| US7612102 | CHIESI | Pre-mixed, ready-to-use pharmaceutical compositions |
Dec, 2027
(3 years from now) | |
Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 30 January, 1992
Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof
Dosage: INJECTABLE;INTRAVENOUS
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER family patents
169. Clindesse patents expiration
CLINDESSE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9789057 | September, 2014 | Decision | Thomas C. Riley et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9789057 | PADAGIS US | Pharmaceutical delivery system |
Dec, 2026
(2 years from now) | |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 30 November, 2004
Treatment: Method of treating bacterial vaginosis
Dosage: CREAM;VAGINAL
CLINDESSE family patents
170. Opana Er patents expiration
OPANA ER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8329216 | August, 2014 | FWD Entered | Endo Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
| US8309122 | January, 2014 | Terminated-Denied | Endo Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
| US8329216 | January, 2014 | FWD Entered | Endo Pharmaceuticals, Inc. | Amneal Pharmaceuticals, LLC |
| US7851482 | December, 2013 | Decision | Jen-Sen Dung et al | |
| US7851482 | November, 2013 | Terminated-Settled | Endo Pharmaceuticals Inc. | Amneal Pharmaceuticals, LLC |
| US8309122 | July, 2009 | Decision | Huai-Hung Kao et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851482 | ENDO PHARMS | Method for making analgesics |
Jul, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8329216 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(1 year, 2 months ago) | |
| US8309122 | ENDO PHARMS | Oxymorphone controlled release formulations |
Feb, 2023
(1 year, 2 months ago) | |
Drugs and Companies using OXYMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
OPANA ER family patents
171. Mirvaso patents expiration
MIRVASO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7439241 | May, 2014 | Decision | Jack Dejovin et al | |
| US8426410 | May, 2014 | Decision | Jack Dejovin et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8426410 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
May, 2025
(1 year, 20 days from now) | |
| US7439241 | GALDERMA LABS LP | Compounds, formulations, and methods for treating or preventing rosacea |
Aug, 2025
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 23, 2016 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 23 August, 2013
Treatment: Topical treatment of facial erythema of rosacea
Dosage: GEL;TOPICAL
MIRVASO family patents
172. Astepro patents expiration
ASTEPRO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8071073 | May, 2014 | Terminated-Denied | Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | MEDA PHARMS | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2012 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 31 August, 2009
Treatment: NA
Dosage: SPRAY, METERED;NASAL
ASTEPRO family patents
173. Astepro patents expiration
ASTEPRO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8071073 | May, 2014 | Terminated-Denied | Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 15, 2011 |
| New Patient Population(NPP) | Aug 30, 2016 |
| M(M-129) | Aug 30, 2016 |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: NA
Dosage: SPRAY, METERED;NASAL
ASTEPRO family patents
174. Astepro Allergy patents expiration
ASTEPRO ALLERGY IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8071073 | May, 2014 | Terminated-Denied | Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: NA
Dosage: SPRAY, METERED;NASAL
ASTEPRO ALLERGY family patents
175. Children's Astepro Allergy patents expiration
CHILDREN'S ASTEPRO ALLERGY IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8071073 | May, 2014 | Terminated-Denied | Meda Pharmaceuticals Inc. | Impax Laboratories, Inc. |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071073 | BAYER HLTHCARE | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(4 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 June, 2021
Treatment: NA
Dosage: SPRAY, METERED;NASAL
CHILDREN'S ASTEPRO ALLERGY family patents
176. Omegaven patents expiration
OMEGAVEN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9566260 | March, 2014 | Decision | Mark Puder et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566260 | FRESENIUS KABI USA | Treatment and prevention of liver disease associated with parenteral nutrition (PN) |
Jul, 2025
(1 year, 2 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-202) | Jul 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Jul 27, 2023 |
Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient
NCE-1 date: 27 July, 2022
Market Authorisation Date: 27 July, 2018
Treatment: Treatment of liver disease through nutrition for patients under the age of 12
Dosage: EMULSION;INTRAVENOUS
OMEGAVEN family patents
177. Levemir Flexpen patents expiration
LEVEMIR FLEXPEN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9265893 | January, 2014 | Decision | Torben Stroem Hansen et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-117) | May 18, 2015 |
| M(M-115) | Apr 06, 2015 |
Drugs and Companies using INSULIN DETEMIR RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN family patents
178. Novolog Flexpen patents expiration
NOVOLOG FLEXPEN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9265893 | January, 2014 | Decision | Torben Stroem Hansen et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
Drugs and Companies using INSULIN ASPART RECOMBINANT ingredient
Market Authorisation Date: 31 October, 2013
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG FLEXPEN family patents
179. Novolog Mix 70/30 Flexpen patents expiration
NOVOLOG MIX 70/30 FLEXPEN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9265893 | January, 2014 | Decision | Torben Stroem Hansen et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9265893 | NOVO NORDISK INC | Injection button |
Sep, 2032
(8 years from now) | |
Market Authorisation Date: 01 November, 2001
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS
NOVOLOG MIX 70/30 FLEXPEN family patents
180. Vazalore patents expiration
VAZALORE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8865187 | January, 2014 | Decision | Lenard M. Lichtenberger | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8865187 | PLX PHARMA | Compositions comprising lecithin oils and NSAIDs for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
Mar, 2022
(2 years ago) | |
Drugs and Companies using ASPIRIN ingredient
Market Authorisation Date: 26 February, 2021
Treatment: NA
Dosage: CAPSULE;ORAL
VAZALORE family patents
181. Acuvue Theravision With Ketotifen patents expiration
ACUVUE THERAVISION WITH KETOTIFEN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9962376 | November, 2013 | Decision | Ranganath R. Raja et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9962376 | JOHNSON JOHNSON VISN | Methods and ophthalmic devices used in the treatment of ocular allergies |
Jun, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2025 |
Drugs and Companies using KETOTIFEN FUMARATE ingredient
Market Authorisation Date: 25 February, 2022
Treatment: NA
Dosage: DRUG-ELUTING CONTACT LENS;OPHTHALMIC
ACUVUE THERAVISION WITH KETOTIFEN family patents
182. Osphena patents expiration
OSPHENA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9566252 | August, 2013 | Decision | Kaija Halonen et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566252 | DUCHESNAY | Method for the alleviation of dyspareunia in women |
Nov, 2022
(1 year, 6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-793) | Jan 25, 2022 |
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2018 |
Drugs and Companies using OSPEMIFENE ingredient
NCE-1 date: 26 February, 2017
Market Authorisation Date: 26 February, 2013
Treatment: Treatment of dyspareunia associated with menopause
Dosage: TABLET;ORAL
OSPHENA family patents
183. Genvoya patents expiration
GENVOYA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9891239 | August, 2013 | Decision | Manoj C. Desai et al | |
| US8633219 | August, 2011 | Decision | Yuji Matsuzaki et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
GENVOYA family patents
184. Stribild patents expiration
STRIBILD IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9891239 | August, 2013 | Decision | Manoj C. Desai et al | |
| US8633219 | August, 2011 | Decision | Yuji Matsuzaki et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9891239 | GILEAD SCIENCES INC | Modulators of pharmacokinetic properties of therapeutics |
Sep, 2029
(5 years from now) | |
| US8633219 | GILEAD SCIENCES INC | Combination therapy |
Apr, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-704) | Dec 17, 2017 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
| New Product(NP) | Aug 27, 2015 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
STRIBILD family patents
185. Xelpros patents expiration
XELPROS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9629852 | June, 2013 | Decision | Ajay Jaysingh Khopade et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9629852 | SUN PHARM | Ophthalmic composition comprising a prostaglandin |
Sep, 2029
(5 years from now) | |
Drugs and Companies using LATANOPROST ingredient
Market Authorisation Date: 12 September, 2018
Treatment: NA
Dosage: EMULSION;OPHTHALMIC
XELPROS family patents
186. Bunavail patents expiration
BUNAVAIL IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9522188 | December, 2012 | Decision | Andrew Finn et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9522188 | BDSI | Abuse resistant transmucosal drug delivery device |
Apr, 2035
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 06, 2017 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 06 June, 2014
Treatment: NA
Dosage: FILM;BUCCAL
BUNAVAIL family patents
187. Caldolor patents expiration
CALDOLOR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9295639 | December, 2012 | Decision | Leo PAVLIV et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9295639 | CUMBERLAND PHARMS | Treating critically ill patients with intravenous ibuprofen |
Sep, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-128) | Nov 19, 2024 |
| New Patient Population(NPP) | May 11, 2026 |
| New Product(NP) | Jun 11, 2012 |
| New Dosing Schedule(D-152) | Nov 20, 2018 |
Drugs and Companies using IBUPROFEN ingredient
Market Authorisation Date: 11 June, 2009
Treatment: Methods of treating pain, inflammation and/or fever in a critically ill patient with intravenous ibuprofen in need thereof
Dosage: SOLUTION;INTRAVENOUS
CALDOLOR family patents
188. Vyxeos patents expiration
VYXEOS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9271931 | October, 2012 | Decision | Paul Tardi et al | |
| US8518437 | December, 2010 | Decision | Paul Tardi et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518437 | CELATOR PHARMS | Lipid carrier compositions with enhanced blood stability |
Jun, 2026
(2 years from now) | |
| US9271931 | CELATOR PHARMS | Compositions for delivery of drug combinations |
Jan, 2027
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-350) | Mar 30, 2028 |
| New Patient Population(NPP) | Mar 30, 2024 |
| Orphan Drug Exclusivity(ODE-287) | Aug 03, 2024 |
| New Product(NP) | Aug 03, 2020 |
Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: POWDER;INTRAVENOUS
VYXEOS family patents
189. Dextenza patents expiration
DEXTENZA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9254267 | August, 2012 | Decision | Amarpreet S. Sawhney | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254267 | OCULAR THERAPEUTIX | Composite hydrogel drug delivery systems |
Sep, 2024
(4 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-876) | Oct 07, 2024 |
| New Indication(I-800) | Jun 20, 2022 |
| New Product(NP) | Nov 30, 2021 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: NA
Dosage: INSERT;OPHTHALMIC
DEXTENZA family patents
190. Leqvio patents expiration
LEQVIO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US10590418 | April, 2012 | Decision | Mark A. Kay et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10590418 | NOVARTIS | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
Jul, 2022
(1 year, 9 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: 22 December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascv...
Dosage: SOLUTION;SUBCUTANEOUS
LEQVIO family patents
191. Brisdelle patents expiration
BRISDELLE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8658663 | January, 2012 | Decision | Patricia Allison Tewes Richards | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8658663 | SEBELA IRELAND LTD | Method of treating thermoregulatory disfunction with paroxetine |
Apr, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jun 28, 2016 |
Drugs and Companies using PAROXETINE MESYLATE ingredient
Market Authorisation Date: 28 June, 2013
Treatment: Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: CAPSULE;ORAL
BRISDELLE family patents
192. Akeega patents expiration
AKEEGA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8859562 | October, 2011 | Decision | Thomas Helleday | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859562 | JANSSEN BIOTECH | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
Drugs and Companies using ABIRATERONE ACETATE; NIRAPARIB TOSYLATE ingredient
Market Authorisation Date: 11 August, 2023
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET;ORAL
AKEEGA family patents
193. Lynparza patents expiration
LYNPARZA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8859562 | October, 2011 | Decision | Thomas Helleday | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859562 | ASTRAZENECA | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-83) | Dec 19, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2019 |
Drugs and Companies using OLAPARIB ingredient
NCE-1 date: 19 December, 2018
Market Authorisation Date: 19 December, 2014
Treatment: Maintenance treatment of gbrca- or sbrca-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemoth...
Dosage: CAPSULE;ORAL; TABLET;ORAL
LYNPARZA family patents
194. Rubraca patents expiration
RUBRACA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8859562 | October, 2011 | Decision | Thomas Helleday | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859562 | ZR PHARMA | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-168) | Apr 06, 2025 |
| Orphan Drug Exclusivity(ODE-126) | Dec 19, 2023 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2021 |
| New Indication(I-830) | May 15, 2023 |
| Orphan Drug Exclusivity(ODE) | Dec 19, 2023 |
| New Indication(I-772) | Apr 06, 2021 |
Drugs and Companies using RUCAPARIB CAMSYLATE ingredient
NCE-1 date: 19 December, 2020
Market Authorisation Date: 19 December, 2016
Treatment: A method for treating metastatic castration-resistant prostate cancer (mcrpc), wherein the cancer is associated with a deleterious brca-mutation
Dosage: TABLET;ORAL
RUBRACA family patents
195. Zejula patents expiration
ZEJULA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8859562 | October, 2011 | Decision | Thomas Helleday | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8859562 | GLAXOSMITHKLINE | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-133) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-277) | Oct 23, 2026 |
| Orphan Drug Exclusivity(ODE-295) | Apr 29, 2027 |
| Orphan Drug Exclusivity(ODE) | Mar 27, 2024 |
| Orphan Drug Exclusivity(ODE-278) | Oct 23, 2026 |
| New Indication(I-814) | Oct 23, 2022 |
| New Indication(I-833) | Apr 29, 2023 |
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2022 |
| New Indication(I-813) | Oct 23, 2022 |
Drugs and Companies using NIRAPARIB TOSYLATE ingredient
NCE-1 date: 27 March, 2021
Market Authorisation Date: 27 March, 2017
Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status
Dosage: TABLET;ORAL
ZEJULA family patents
196. Mirapex Er patents expiration
MIRAPEX ER IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8679533 | September, 2011 | Decision | Ernest J. Lee et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8679533 | BOEHRINGER INGELHEIM | Pramipexole once-daily dosage form |
Sep, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-623) | Mar 19, 2013 |
| New Dosage Form(NDF) | Feb 19, 2013 |
Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient
Market Authorisation Date: 19 February, 2010
Treatment: Treatment of parkinson's disease
Dosage: TABLET, EXTENDED RELEASE;ORAL
MIRAPEX ER family patents
197. Silenor patents expiration
SILENOR IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8513299 | August, 2011 | Decision | Roberta L. Rogowski et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8513299 | CURRAX | Methods of using low-dose doxepin for the improvement of sleep |
Sep, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 17, 2013 |
Drugs and Companies using DOXEPIN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 March, 2010
Treatment: Treatment of insomnia
Dosage: TABLET;ORAL
SILENOR family patents
198. Phoslyra patents expiration
PHOSLYRA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8591938 | May, 2011 | Decision | Stephen C. Tarallo | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8591938 | FRESENIUS MEDCL | Liquid compositions of calcium acetate |
Feb, 2030
(5 years from now) | |
Drugs and Companies using CALCIUM ACETATE ingredient
Market Authorisation Date: 18 April, 2011
Treatment: Use of phoslyra for reduction of serum phosphorous in patients
Dosage: SOLUTION;ORAL
PHOSLYRA family patents
199. Rydapt patents expiration
RYDAPT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8575146 | January, 2011 | Decision | Steven Coutre | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8575146 | NOVARTIS | Pharmaceutical uses of staurosporine derivatives |
Dec, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-140) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE-141) | Apr 28, 2024 |
| Orphan Drug Exclusivity(ODE) | Apr 28, 2024 |
| New Chemical Entity Exclusivity(NCE) | Apr 28, 2022 |
Drugs and Companies using MIDOSTAURIN ingredient
NCE-1 date: 28 April, 2021
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of adult patients with aggressive systemic mastocytosis (asm), systemic mastocytosis with associated hematological neoplasm (sm-ahn), or mast cell leukemia (mcl)
Dosage: CAPSULE;ORAL
RYDAPT family patents
200. Givlaari patents expiration
GIVLAARI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US9150605 | November, 2010 | Decision | Charles Allerson et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9150605 | ALNYLAM PHARMS INC | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
Aug, 2025
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2024 |
| Orphan Drug Exclusivity(ODE-273) | Nov 20, 2026 |
Drugs and Companies using GIVOSIRAN SODIUM ingredient
NCE-1 date: 21 November, 2023
Market Authorisation Date: 20 November, 2019
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
GIVLAARI family patents
201. Acular Ls patents expiration
ACULAR LS IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8008338 | November, 2010 | Decision | Christopher A. Muller et al | |
| US8008338 | August, 2006 | Decision | Christopher A. Muller et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8008338 | ABBVIE | Ketorolac tromethamine compositions for treating or preventing ocular pain |
May, 2027
(3 years from now) | |
Drugs and Companies using KETOROLAC TROMETHAMINE ingredient
Market Authorisation Date: 30 May, 2003
Treatment: A method of treating or preventing ocular pain in a patient
Dosage: SOLUTION/DROPS;OPHTHALMIC
ACULAR LS family patents
202. Vusion patents expiration
VUSION IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8147852 | November, 2010 | Decision | Marcel Borgers et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8147852 | MYLAN | Modified azole compounds as antifungal and antibacterial agents |
Mar, 2028
(3 years from now) | |
Drugs and Companies using MICONAZOLE NITRATE; WHITE PETROLATUM; ZINC OXIDE ingredient
Market Authorisation Date: 16 February, 2006
Treatment: Use for treatment of diaper dermatitis complicated by candidiasis
Dosage: OINTMENT;TOPICAL
VUSION family patents
203. Daklinza patents expiration
DAKLINZA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US8329159 | August, 2010 | Decision | Makonen Belema et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8329159 | BRISTOL-MYERS SQUIBB | Hepatitis C virus inhibitors |
Jul, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-727) | Feb 05, 2019 |
| New Indication(I-726) | Feb 05, 2019 |
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2020 |
| New Dosing Schedule(D-161) | Feb 05, 2019 |
| New Dosing Schedule(D-162) | Feb 05, 2019 |
Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient
NCE-1 date: 25 July, 2019
Market Authorisation Date: 24 July, 2015
Treatment: NA
Dosage: TABLET;ORAL
DAKLINZA family patents
204. Pristiq patents expiration
PRISTIQ IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US6673838 | May, 2010 | Decision | Anthony F. Hadfield et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Mar, 2022
(2 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Feb, 2022
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-675) | Feb 14, 2016 |
| M(M-222) | Feb 06, 2021 |
| New Chemical Entity Exclusivity(NCE) | Mar 01, 2013 |
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
NCE-1 date: 01 March, 2012
Market Authorisation Date: 20 August, 2014
Treatment: For the approved uses and conditions of use, including depression; Maintenance treatment of major depressive disorder (mdd)
Dosage: TABLET, EXTENDED RELEASE;ORAL
PRISTIQ family patents
205. Triferic patents expiration
TRIFERIC IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7857977 | February, 2009 | Decision | Lori L. Wash | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7857977 | ROCKWELL MEDICAL INC | Packaging of ferric pyrophosphate for dialysis |
Sep, 2027
(3 years from now) | |
Drugs and Companies using FERRIC PYROPHOSPHATE CITRATE ingredient
Market Authorisation Date: 25 April, 2016
Treatment: Method of iron administration to treat patients in need of iron replacement
Dosage: POWDER;INTRAVENOUS
TRIFERIC family patents
206. Lumigan patents expiration
LUMIGAN IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7851504 | January, 2009 | Decision | Chin-Ming Chang et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7851504 | ABBVIE | Enhanced bimatoprost ophthalmic solution |
Jun, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 31, 2013 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 31 August, 2010
Treatment: NA
Dosage: SOLUTION/DROPS;OPHTHALMIC
LUMIGAN family patents
207. Venlafaxine Besylate patents expiration
VENLAFAXINE BESYLATE IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7776358 | December, 2008 | Decision | Joan Cucala Escoi et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776358 | ALMATICA | Extended release venlafaxine besylate tablets |
May, 2028
(4 years from now) | |
Drugs and Companies using VENLAFAXINE BESYLATE ingredient
Market Authorisation Date: 29 June, 2022
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE BESYLATE family patents
208. Balcoltra patents expiration
BALCOLTRA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7838042 | December, 2008 | Decision | Max R. Motyka et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7838042 | AVION PHARMS | Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions |
Jun, 2027
(3 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient
Market Authorisation Date: 09 January, 2018
Treatment: Administration of ferrous bisglycinate tablets
Dosage: TABLET;ORAL
BALCOLTRA family patents
209. Forfivo Xl patents expiration
FORFIVO XL IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7674479 | December, 2008 | Decision | Horst G. Zerbe et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7674479 | TWI PHARMS | Sustained-release bupropion and bupropion/mecamylamine tablets |
Jun, 2027
(3 years from now) | |
Drugs and Companies using BUPROPION HYDROCHLORIDE ingredient
Market Authorisation Date: 10 November, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
FORFIVO XL family patents
210. Sfrowasa patents expiration
SFROWASA IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7645801 | April, 2008 | Decision | Bala VENKATARAMAN et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7645801 | MYLAN SPECIALITY LP | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
Jul, 2027
(3 years from now) | |
Drugs and Companies using MESALAMINE ingredient
Market Authorisation Date: 24 December, 1987
Treatment: NA
Dosage: ENEMA;RECTAL
SFROWASA family patents
211. Ixempra Kit patents expiration
IXEMPRA KIT IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7312237 | January, 2007 | Decision | Francis Y.F. Lee | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7312237 | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Aug, 2024
(3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2012 |
| M(M-61) | Oct 18, 2014 |
| Pediatric Exclusivity(PED) | Apr 18, 2015 |
Drugs and Companies using IXABEPILONE ingredient
NCE-1 date: 18 April, 2014
Market Authorisation Date: 16 October, 2007
Treatment: Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer
Dosage: INJECTABLE;INTRAVENOUS
IXEMPRA KIT family patents
212. Kynamro patents expiration
KYNAMRO IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7015315 | September, 2004 | Decision | COOK et al | |
| US7015315 | October, 2000 | Decision | COOK et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7015315 | KASTLE THERAPS LLC | Gapped oligonucleotides |
Mar, 2023
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-41) | Jan 29, 2020 |
| Orphan Drug Exclusivity(ODE) | Jan 29, 2020 |
| New Chemical Entity Exclusivity(NCE) | Jan 29, 2018 |
Drugs and Companies using MIPOMERSEN SODIUM ingredient
NCE-1 date: 29 January, 2017
Market Authorisation Date: 29 January, 2013
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
KYNAMRO family patents
213. Tegsedi patents expiration
TEGSEDI IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7015315 | September, 2004 | Decision | COOK et al | |
| US7015315 | October, 2000 | Decision | COOK et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7015315 | AKCEA THERAPS | Gapped oligonucleotides |
Mar, 2023
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-212) | Oct 05, 2025 |
| New Chemical Entity Exclusivity(NCE) | Oct 05, 2023 |
Drugs and Companies using INOTERSEN SODIUM ingredient
NCE-1 date: 05 October, 2022
Market Authorisation Date: 05 October, 2018
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
TEGSEDI family patents
214. Banzel patents expiration
BANZEL IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US6740669 | April, 2003 | Decision | ROBERT PORTMANN et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6740669 | EISAI INC | Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic |
Nov, 2022
(1 year, 5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | May 14, 2016 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2013 |
| Orphan Drug Exclusivity(ODE) | Nov 14, 2015 |
Drugs and Companies using RUFINAMIDE ingredient
NCE-1 date: 15 May, 2015
Market Authorisation Date: 03 March, 2011
Treatment: NA
Dosage: SUSPENSION;ORAL; TABLET;ORAL
BANZEL family patents
215. Vistogard patents expiration
VISTOGARD IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US7776838 | April, 2002 | Decision | VON BORSTEL et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7776838 | BTG INTL | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
Aug, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-104) | Dec 11, 2022 |
| Orphan Drug Exclusivity(ODE) | Dec 11, 2022 |
| New Product(NP) | Dec 11, 2018 |
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2020 |
Drugs and Companies using URIDINE TRIACETATE ingredient
NCE-1 date: 05 September, 2019
Market Authorisation Date: 11 December, 2015
Treatment: Emergency treatment of adult & pediatric patients following fluorouracil or capecitabine overdose,or who exhibit early-onset,severe or life-threatening cardiac or cns toxicity or unusually severe adve...
Dosage: GRANULE;ORAL
VISTOGARD family patents
216. Fusilev patents expiration
FUSILEV IPR and PTAB Proceedings
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
| | ||||
| US6500829 | March, 1998 | Decision | WOOD et al | |
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6500829 | ACROTECH BIOPHARMA | Substantially pure diastereoisomers of tetrahydrofolate derivatives |
Mar, 2022
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-10) | Apr 29, 2018 |
| Orphan Drug Exclusivity(ODE) | Mar 07, 2015 |
| New Indication(I-637) | Apr 29, 2014 |
Drugs and Companies using LEVOLEUCOVORIN CALCIUM ingredient
Market Authorisation Date: 07 March, 2008
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS; POWDER;INTRAVENOUS
FUSILEV family patents